

Table 19.1
Non-Hodgkin Lymphoma

Trends in SEER Incidence^{ab} and U.S. Mortality^c Using the Joinpoint Regression Program,
1975-2011 With up to Five Joinpoints, 1992-2011 With up to Three Joinpoints,
Both Sexes by Race/Ethnicity

	JP Trend 1		JP Trend 2		JP Trend 3		JP Trend 4		JP Trend 5		JP Trend 6		AAPC ^d	
	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	2002-11	2007-11
<u>SEER 9 Delay-Adjusted Incidence^a, 1975-2011</u>														
All Races	1975-91	3.7*	1991-11	0.6*									0.6*	0.6*
White	1975-90	3.8*	1990-07	0.9*	2007-11	-0.7							0.2	-0.7
Black	1975-94	4.5*	1994-11	0.6									0.6	0.6
<u>SEER 13 Delay-Adjusted Incidence^b, 1992-2011</u>														
All Races	1992-11	0.4*											0.4*	0.4*
White	1992-11	0.6*											0.6*	0.6*
Black	1992-11	0.8*											0.8*	0.8*
<u>SEER 9 Observed Incidence^a, 1975-2011</u>														
All Races	1975-91	3.7*	1991-11	0.5*									0.5*	0.5*
White	1975-90	3.8*	1990-07	0.8*	2007-11	-1.6*							-0.3	-1.6*
Black	1975-94	4.6*	1994-11	0.3									0.3	0.3
<u>SEER 13 Observed Incidence^b, 1992-2011</u>														
All Races	1992-11	0.3*											0.3*	0.3*
White	1992-09	0.6*	2009-11	-3.4									-0.3	-1.4
White NH ^{ef}	1992-09	0.7*	2009-11	-3.8									-0.4	-1.6
Black	1992-11	0.5*											0.5*	0.5*
Black NH ^{ef}	1992-11	0.6*											0.6*	0.6*
API ^e	1992-11	0.3											0.3	0.3
AI/AN ^{eg}	1992-11	2.4*											2.4*	2.4*
Hispanic ^f	1992-11	0.5*											0.5*	0.5*
<u>U.S. Cancer Mortality^c, 1975-2011</u>														
All Races	1975-91	2.5*	1991-97	1.6*	1997-06	-3.1*	2006-11	-2.2*					-2.6*	-2.2*
White	1975-91	2.5*	1991-97	1.6*	1997-06	-3.1*	2006-11	-2.2*					-2.6*	-2.2*
Black	1975-96	2.7*	1996-11	-2.5*									-2.5*	-2.5*
<u>U.S. Cancer Mortality^c, 1992-2011</u>														
All Races	1992-97	1.7*	1997-06	-3.1*	2006-11	-2.2*							-2.6*	-2.2*
White	1992-97	1.7*	1997-06	-3.1*	2006-11	-2.2*							-2.6*	-2.2*
White NH ^{ef}	1992-94	3.6*	1994-97	1.2	1997-06	-3.0*	2006-11	-2.3*					-2.6*	-2.3*
Black	1992-97	1.7	1997-11	-2.5*									-2.5*	-2.5*
Black NH ^{ef}	1992-96	3.1	1996-11	-2.3*									-2.3*	-2.3*
API ^e	1992-11	-2.0*											-2.0*	-2.0*
AI/AN ^{eg}	1992-11	-0.4											-0.4	-0.4
Hispanic ^f	1992-97	3.1*	1997-03	-3.7*	2003-11	-1.1*							-1.4*	-1.1*

Joinpoint Regression Program Version 4.1.0, April 2014, National Cancer Institute. (<http://surveillance.cancer.gov/joinpoint/>).
^a The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
^b Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).
^c Trends are from the SEER 13 areas (SEER 9 Areas, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Registry).
^d Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.
^e The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint.
^f API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic
Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
The Hispanic and Non-Hispanic mortality trends exclude deaths from New Hampshire and Oklahoma.
^g Data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.
* The APC/AAPC is significantly different from zero (p<.05).
- Joinpoint regression line analysis could not be performed on data series.

Table 19.2
Non-Hodgkin Lymphoma

Trends in SEER Incidence^{ab} and U.S. Mortality^c Using the Joinpoint Regression Program,
1975-2011 With up to Five Joinpoints, 1992-2011 With up to Three Joinpoints,
Males by Race/Ethnicity

	JP Trend 1		JP Trend 2		JP Trend 3		JP Trend 4		JP Trend 5		JP Trend 6		AAPC ^d	
	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	2002-11	2007-11
<u>SEER 9 Delay-Adjusted Incidence^a, 1975-2011</u>														
All Races	1975-91	4.2*	1991-11	0.4*									0.4*	0.4*
White	1975-90	4.5*	1990-11	0.6*									0.6*	0.6*
Black	1975-94	5.4*	1994-11	-0.1									-0.1	-0.1
<u>SEER 13 Delay-Adjusted Incidence^b, 1992-2011</u>														
All Races	1992-11	0.3*											0.3*	0.3*
White	1992-11	0.4*											0.4*	0.4*
Black	1992-11	0.1											0.1	0.1
<u>SEER 9 Observed Incidence^a, 1975-2011</u>														
All Races	1975-91	4.2*	1991-11	0.3*									0.3*	0.3*
White	1975-90	4.5*	1990-11	0.4*									0.4*	0.4*
Black	1975-94	5.4*	1994-11	-0.4									-0.4	-0.4
<u>SEER 13 Observed Incidence^b, 1992-2011</u>														
All Races	1992-11	0.2											0.2	0.2
White	1992-95	2.7	1995-98	-2.0	1998-09	0.7*	2009-11	-2.9					-0.1	-1.1
White NH ^{ef}	1992-95	2.9	1995-98	-1.9	1998-09	0.8*	2009-11	-3.5					-0.2	-1.4
Black	1992-11	-0.2											-0.2	-0.2
Black NH ^{ef}	1992-11	-0.1											-0.1	-0.1
API ^e	1992-11	0.2											0.2	0.2
AI/AN ^{eg}	1992-11	1.5											1.5	1.5
Hispanic ^f	1992-11	0.3											0.3	0.3
<u>U.S. Cancer Mortality^c, 1975-2011</u>														
All Races	1975-91	2.7*	1991-97	1.6*	1997-06	-2.9*	2006-11	-1.8*					-2.3*	-1.8*
White	1975-96	2.5*	1996-11	-2.5*									-2.5*	-2.5*
Black	1975-96	2.7*	1996-11	-2.5*									-2.5*	-2.5*
<u>U.S. Cancer Mortality^c, 1992-2011</u>														
All Races	1992-97	1.7*	1997-06	-2.9*	2006-11	-1.8*							-2.3*	-1.8*
White	1992-97	1.4*	1997-11	-2.6*									-2.6*	-2.6*
White NH ^{ef}	1992-97	1.8*	1997-11	-2.6*									-2.6*	-2.6*
Black	1992-96	2.8	1996-11	-2.4*									-2.4*	-2.4*
Black NH ^{ef}	1992-96	3.0	1996-11	-2.3*									-2.3*	-2.3*
API ^e	1992-11	-2.2*											-2.2*	-2.2*
AI/AN ^{eg}	1992-11	-0.6											-0.6	-0.6
Hispanic ^f	1992-96	2.7	1996-11	-2.3*									-2.3*	-2.3*

Joinpoint Regression Program Version 4.1.0, April 2014, National Cancer Institute. (<http://surveillance.cancer.gov/joinpoint/>).

The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Trends are from the SEER 13 areas (SEER 9 Areas, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Registry).

Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint.

API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska

Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

The Hispanic and Non-Hispanic mortality trends exclude deaths from New Hampshire and Oklahoma.

Data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

* The APC/AAPC is significantly different from zero ($p < .05$).

- Joinpoint regression line analysis could not be performed on data series.

Table 19.3
Non-Hodgkin Lymphoma

Trends in SEER Incidence^{ab} and U.S. Mortality^c Using the Joinpoint Regression Program,
1975-2011 With up to Five Joinpoints, 1992-2011 With up to Three Joinpoints,
Females by Race/Ethnicity

	JP Trend 1		JP Trend 2		JP Trend 3		JP Trend 4		JP Trend 5		JP Trend 6		AAPC ^d	
	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	2002-11	2007-11
<u>SEER 9 Delay-Adjusted Incidence^a, 1975-2011</u>														
All Races	1975-88	3.0*	1988-04	1.4*	2004-11	-0.6							-0.2	-0.6
White	1975-88	3.0*	1988-04	1.5*	2004-11	-0.5							-0.1	-0.5
Black	1975-04	3.0*	2004-11	-0.7									0.1	-0.7
<u>SEER 13 Delay-Adjusted Incidence^b, 1992-2011</u>														
All Races	1992-04	1.3*	2004-11	-0.5									-0.1	-0.5
White	1992-04	1.4*	2004-11	-0.4									0.0	-0.4
Black	1992-98	5.5*	1998-11	0.7									0.7	0.7
<u>SEER 9 Observed Incidence^a, 1975-2011</u>														
All Races	1975-88	3.0*	1988-04	1.4*	2004-11	-0.9*							-0.4	-0.9*
White	1975-88	3.0*	1988-04	1.4*	2004-11	-1.0*							-0.5	-1.0*
Black	1975-04	2.9*	2004-11	-1.4									-0.5	-1.4
<u>SEER 13 Observed Incidence^b, 1992-2011</u>														
All Races	1992-04	1.3*	2004-11	-0.7									-0.3	-0.7
White	1992-04	1.4*	2004-11	-0.8									-0.3	-0.8
White NH ^{ef}	1992-04	1.5*	2004-11	-1.0*									-0.4	-1.0*
Black	1992-98	5.6*	1998-11	0.3									0.3	0.3
Black NH ^{ef}	1992-98	5.5*	1998-11	0.4									0.4	0.4
API ^e	1992-11	0.4											0.4	0.4
AI/AN ^{eg}	1992-11	3.0*											3.0*	3.0*
Hispanic ^f	1992-11	0.9*											0.9*	0.9*
<u>U.S. Cancer Mortality^c, 1975-2011</u>														
All Races	1975-94	2.2*	1994-97	0.9	1997-11	-3.2*							-3.2*	-3.2*
White	1975-96	2.2*	1996-11	-3.1*									-3.1*	-3.1*
Black	1975-97	2.6*	1997-11	-2.7*									-2.7*	-2.7*
<u>U.S. Cancer Mortality^c, 1992-2011</u>														
All Races	1992-94	3.4*	1994-98	0.1	1998-04	-3.6*	2004-11	-2.9*					-3.1*	-2.9*
White	1992-94	3.5*	1994-98	0.1	1998-03	-3.8*	2003-11	-2.9*					-3.0*	-2.9*
White NH ^{ef}	1992-94	3.8*	1994-97	0.9	1997-11	-3.2*							-3.2*	-3.2*
Black	1992-97	2.0	1997-11	-2.5*									-2.5*	-2.5*
Black NH ^{ef}	1992-97	2.3	1997-11	-2.5*									-2.5*	-2.5*
API ^e	1992-11	-1.6*											-1.6*	-1.6*
AI/AN ^{eg}	1992-11	-0.3											-0.3	-0.3
Hispanic ^f	1992-97	2.9	1997-11	-2.1*									-2.1*	-2.1*

Joinpoint Regression Program Version 4.1.0, April 2014, National Cancer Institute. (<http://surveillance.cancer.gov/joinpoint/>).

The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Trends are from the SEER 13 areas (SEER 9 Areas, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Registry).

Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint.

API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska

Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

The Hispanic and Non-Hispanic mortality trends exclude deaths from New Hampshire and Oklahoma.

Data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

* The APC/AAPC is significantly different from zero ($p < .05$).

- Joinpoint regression line analysis could not be performed on data series.

Table 19.4
Non-Hodgkin Lymphoma

Delay-adjusted SEER Incidence^a Rates by Year, Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Year of Diagnosis:									
1975	11.07	12.89	9.59	11.61	13.49	10.11	6.36	7.31	5.31
1976	11.21	12.82	10.04	11.65	13.27	10.51	5.95	7.45	4.87
1977	11.18	12.93	9.82	11.64	13.52	10.20	6.64	7.23	6.10
1978	11.92	14.28	10.12	12.48	14.77	10.74	7.15	9.46	5.17
1979	12.52	14.20	11.21	13.00	14.60	11.77	8.39	11.81	5.91
1980	12.62	15.01	10.81	12.97	15.26	11.22	8.77	10.89	7.20
1981	13.58	15.90	11.81	14.06	16.35	12.35	7.42	10.59	4.98
1982	13.39	15.56	11.61	14.02	16.42	12.05	10.27	10.22	10.01
1983	13.99	16.62	11.95	14.64	17.53	12.41	10.28	10.89	9.62
1984	15.19	18.30	12.78	15.96	19.10	13.52	9.47	12.52	6.92
1985	15.51	18.37	13.18	16.29	19.23	13.87	9.89	11.96	8.33
1986	15.92	19.43	13.03	16.83	20.56	13.77	10.67	13.13	8.52
1987	16.75	20.79	13.42	17.71	22.15	14.01	10.49	10.56	10.10
1988	17.25	21.33	14.08	18.22	22.43	14.91	11.59	15.80	8.49
1989	17.36	21.65	13.85	18.37	23.04	14.52	11.64	14.18	9.73
1990	18.52	22.99	14.82	19.37	23.96	15.55	13.83	17.54	10.93
1991	18.81	23.74	14.60	19.69	24.83	15.30	14.04	18.74	10.38
1992	18.64	23.06	14.95	19.58	23.97	15.85	13.64	18.75	9.66
1993	18.87	23.48	15.02	19.67	24.34	15.72	14.09	19.40	9.73
1994	19.97	24.98	15.81	20.70	25.60	16.58	14.46	21.62	8.75
1995	19.99	25.44	15.43	20.71	26.18	16.06	16.71	23.60	11.36
1996	19.45	24.26	15.51	20.32	25.29	16.24	15.34	18.92	12.31
1997	20.01	24.53	16.47	20.93	25.28	17.50	16.28	24.08	10.79
1998	19.64	22.99	16.87	20.64	24.07	17.79	14.39	16.77	12.49
1999	19.97	24.61	16.32	20.97	25.55	17.34	14.36	18.53	11.19
2000	19.77	24.28	16.12	20.96	25.67	17.12	13.94	18.36	10.66
2001	20.05	24.42	16.50	20.90	25.51	17.15	16.14	18.43	14.09
2002	20.26	24.26	17.10	21.42	25.63	18.02	14.57	17.36	12.49
2003	20.82	25.08	17.59	22.06	26.50	18.60	16.14	19.66	13.69
2004	21.48	26.03	17.99	22.53	27.10	18.98	18.75	24.45	14.62
2005	20.93	25.73	17.11	22.22	27.00	18.34	16.99	20.37	14.25
2006	20.58	24.77	17.33	21.98	26.29	18.59	16.50	20.92	13.23
2007	21.35	26.23	17.46	22.81	27.91	18.63	15.81	19.11	13.33
2008	20.97	25.76	17.07	22.06	27.10	17.89	17.16	19.33	15.22
2009	20.95	25.28	17.44	22.26	26.98	18.31	15.66	19.11	13.12
2010	21.49	26.70	17.25	22.70	27.84	18.49	18.16	23.69	13.77
2011	20.20	24.77	16.58	21.51	26.34	17.63	15.26	18.27	13.03

Additional information on the model used to delay-adjust SEER Incidence rates can be found at [\(http://surveillance.cancer.gov/delay/\)](http://surveillance.cancer.gov/delay/).

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta). Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

- Delay-adjusted rate is not shown for observed rates based on less than 16 cases for the time interval.

Table 19.5
Non-Hodgkin Lymphoma

Age-adjusted SEER Incidence^a Rates by Year, Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Year of Diagnosis:									
1975-2011	18.13	22.21	14.90	18.88	23.06	15.54	13.64	17.17	10.88
1975	11.07	12.89	9.59	11.61	13.49	10.11	6.36	7.31	5.31
1976	11.21	12.82	10.04	11.65	13.27	10.51	5.95	7.45	4.87
1977	11.18	12.93	9.82	11.64	13.52	10.20	6.64	7.23	6.10
1978	11.92	14.28	10.12	12.48	14.77	10.74	7.15	9.46	5.17
1979	12.52	14.20	11.21	13.00	14.60	11.77	8.39	11.81	5.91
1980	12.62	15.01	10.81	12.97	15.26	11.22	8.77	10.89	7.20
1981	13.58	15.90	11.81	14.06	16.35	12.35	7.42	10.59	4.98
1982	13.39	15.56	11.61	14.02	16.42	12.05	10.27	10.22	10.01
1983	13.99	16.62	11.95	14.64	17.52	12.41	10.28	10.88	9.62
1984	15.19	18.29	12.78	15.96	19.10	13.52	9.46	12.52	6.92
1985	15.50	18.37	13.18	16.28	19.23	13.87	9.89	11.96	8.32
1986	15.92	19.43	13.03	16.83	20.56	13.77	10.66	13.13	8.52
1987	16.74	20.79	13.42	17.70	22.14	14.01	10.48	10.55	10.09
1988	17.25	21.32	14.08	18.21	22.42	14.90	11.58	15.79	8.49
1989	17.35	21.65	13.84	18.36	23.02	14.52	11.62	14.17	9.72
1990	18.51	22.98	14.81	19.35	23.95	15.54	13.81	17.51	10.91
1991	18.80	23.73	14.60	19.68	24.81	15.29	14.03	18.72	10.37
1992	18.62	23.04	14.94	19.56	23.95	15.84	13.62	18.73	9.65
1993	18.86	23.46	15.01	19.65	24.31	15.71	14.06	19.37	9.72
1994	19.95	24.96	15.80	20.68	25.57	16.57	14.43	21.58	8.74
1995	19.97	25.41	15.42	20.68	26.14	16.03	16.67	23.54	11.33
1996	19.42	24.23	15.49	20.29	25.24	16.21	15.29	18.86	12.27
1997	19.98	24.49	16.45	20.88	25.22	17.46	16.22	23.99	10.75
1998	19.61	22.95	16.84	20.59	24.01	17.75	14.32	16.70	12.44
1999	19.92	24.56	16.29	20.90	25.46	17.28	14.28	18.42	11.12
2000	19.72	24.22	16.08	20.87	25.56	17.04	13.85	18.23	10.59
2001	19.99	24.35	16.45	20.79	25.38	17.06	16.00	18.27	13.97
2002	20.18	24.18	17.04	21.28	25.47	17.91	14.42	17.19	12.36
2003	20.73	24.97	17.51	21.88	26.29	18.46	15.94	19.42	13.52
2004	21.37	25.90	17.90	22.32	26.84	18.79	18.48	24.08	14.41
2005	20.80	25.57	17.00	21.95	26.69	18.13	16.69	20.00	14.00
2006	20.42	24.59	17.20	21.66	25.91	18.32	16.14	20.46	12.94
2007	21.14	25.98	17.29	22.41	27.43	18.31	15.41	18.63	12.99
2008	20.74	25.48	16.89	21.59	26.53	17.51	16.64	18.75	14.76
2009	20.67	24.94	17.21	21.68	26.28	17.84	15.10	18.42	12.64
2010	21.14	26.26	16.97	21.98	26.95	17.90	17.38	22.67	13.17
2011	19.63	24.07	16.11	20.43	25.01	16.74	14.25	17.06	12.17

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta). Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.6
Non-Hodgkin Lymphoma

Age-adjusted U.S. Death^a Rates by Year, Race and Sex

Year of Death:	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
1975-2011	7.28	9.10	5.95	7.58	9.44	6.21	4.93	6.34	3.90
1975	5.63	6.92	4.65	5.83	7.15	4.82	3.74	4.83	2.92
1976	5.71	6.87	4.83	5.94	7.14	5.03	3.54	4.54	2.76
1977	5.77	6.88	4.92	5.96	7.10	5.10	3.89	4.89	3.12
1978	5.93	7.30	4.90	6.15	7.53	5.12	3.90	5.40	2.81
1979	5.95	7.40	4.88	6.18	7.70	5.08	3.65	4.50	2.98
1980	6.23	7.47	5.29	6.47	7.74	5.52	3.99	5.15	3.12
1981	6.16	7.38	5.27	6.40	7.66	5.47	3.98	5.00	3.25
1982	6.55	7.98	5.49	6.83	8.29	5.74	4.12	5.23	3.29
1983	6.66	8.11	5.58	6.92	8.39	5.85	4.30	5.79	3.23
1984	6.76	8.15	5.75	7.05	8.50	6.01	4.19	5.28	3.39
1985	7.06	8.80	5.80	7.34	9.17	6.02	4.62	5.57	3.87
1986	7.31	8.98	6.05	7.59	9.25	6.33	4.95	6.64	3.70
1987	7.26	8.81	6.10	7.56	9.12	6.38	4.73	6.30	3.62
1988	7.52	9.28	6.24	7.82	9.59	6.53	5.01	6.82	3.72
1989	7.83	9.73	6.43	8.12	10.04	6.71	5.33	7.10	4.07
1990	7.87	9.97	6.34	8.16	10.32	6.58	5.39	7.13	4.17
1991	8.19	10.15	6.74	8.50	10.52	7.00	5.70	7.17	4.61
1992	8.22	10.30	6.69	8.53	10.66	6.96	5.64	7.23	4.45
1993	8.25	10.14	6.86	8.57	10.45	7.17	5.69	7.53	4.40
1994	8.63	10.75	7.10	9.00	11.20	7.41	5.54	6.82	4.56
1995	8.72	10.81	7.16	9.09	11.21	7.49	5.79	7.62	4.45
1996	8.75	10.94	7.14	9.09	11.29	7.46	6.21	8.25	4.74
1997	8.88	11.03	7.25	9.21	11.35	7.57	6.34	8.45	4.87
1998	8.69	10.85	7.10	9.03	11.27	7.38	5.99	7.50	4.89
1999	8.32	10.36	6.85	8.67	10.71	7.18	5.65	7.44	4.41
2000	8.17	10.20	6.70	8.54	10.63	7.01	5.20	6.61	4.17
2001	7.91	9.98	6.42	8.21	10.31	6.68	5.61	7.28	4.47
2002	7.65	9.66	6.19	7.97	10.04	6.44	5.41	6.88	4.41
2003	7.38	9.40	5.92	7.69	9.81	6.13	4.94	5.83	4.27
2004	7.09	8.94	5.73	7.38	9.28	5.96	5.01	6.23	4.13
2005	6.95	8.87	5.56	7.24	9.22	5.79	4.77	6.11	3.81
2006	6.74	8.48	5.44	7.01	8.78	5.66	4.92	6.27	3.93
2007	6.59	8.36	5.26	6.86	8.67	5.49	4.52	5.77	3.62
2008	6.41	8.20	5.09	6.71	8.56	5.33	4.31	5.48	3.45
2009	6.30	8.12	4.93	6.56	8.42	5.13	4.49	6.15	3.41
2010	6.14	7.83	4.85	6.37	8.11	5.04	4.57	5.84	3.64
2011	6.03	7.85	4.64	6.28	8.16	4.83	4.36	5.75	3.40

^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.
Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.7
Non-Hodgkin Lymphoma

SEER Incidence^a and U.S. Death^b Rates, Age-Adjusted and Age-Specific Rates, by Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Incidence</u>									
<u>Age at Diagnosis</u>									
Age-Adjusted Rates, 2007-2011									
All ages	19.7	23.9	16.3	20.6	24.9	17.2	14.3	17.4	11.9
Under 65	9.3	11.1	7.6	9.6	11.3	7.8	8.8	11.1	6.9
65 and over	91.6	112.3	76.9	97.2	118.7	81.8	52.3	61.4	46.9
All ages (IARC world std) ^c	13.0	15.6	10.7	13.6	16.3	11.3	10.3	12.6	8.4
Age-Specific Rates, 2007-2011									
<1	-	-	-	-	-	-	-	-	-
1-4	0.6	0.8	0.5	0.6	0.7	0.5	0.7	-	-
5-9	1.1	1.5	0.7	1.0	1.4	0.6	1.0	1.4	-
10-14	1.3	1.6	0.8	1.3	1.7	0.9	1.3	1.6	1.0
15-19	1.7	2.2	1.2	1.8	2.3	1.3	1.5	1.9	1.2
20-24	2.5	3.1	1.9	2.5	3.2	1.8	2.7	3.5	1.9
25-29	3.5	4.1	2.9	3.4	4.0	2.8	4.5	5.7	3.4
30-34	4.9	5.9	3.9	4.7	5.5	3.8	6.5	8.2	5.0
35-39	7.1	8.4	5.9	7.2	8.6	5.8	8.7	10.8	6.8
40-44	10.3	12.5	8.1	10.5	12.7	8.3	11.0	13.7	8.6
45-49	14.8	17.8	11.9	15.3	18.2	12.4	14.5	18.9	10.5
50-54	21.6	25.4	17.8	22.4	26.4	18.6	20.1	24.3	16.3
55-59	30.7	36.2	25.6	32.1	37.4	27.0	25.8	33.3	19.5
60-64	44.2	51.8	37.2	46.3	54.1	39.0	33.7	40.7	28.1
65-69	65.2	76.6	55.3	69.0	80.4	58.8	45.5	50.7	41.5
70-74	81.4	97.4	68.2	87.4	103.9	73.4	46.9	52.7	42.6
75-79	106.2	129.9	88.3	113.2	137.4	94.4	62.4	75.6	54.0
80-84	119.7	145.4	102.8	126.9	154.2	108.7	59.9	68.6	55.3
85+	112.6	153.3	92.5	117.5	160.0	96.6	52.4	69.5	45.5
<u>U.S. Mortality</u>									
<u>Age at Death</u>									
Age-Adjusted Rates, 2007-2011									
All ages	6.3	8.1	5.0	6.6	8.4	5.2	4.5	5.8	3.5
Under 65	1.6	2.1	1.1	1.6	2.1	1.1	1.9	2.5	1.4
65 and over	38.6	49.3	31.3	40.7	51.8	33.0	22.0	28.4	18.3
All ages (IARC world std) ^c	3.4	4.4	2.6	3.5	4.5	2.7	2.8	3.7	2.1
Age-Specific Rates, 2007-2011									
<1	-	-	-	-	-	-	-	-	-
1-4	0.0	0.0	-	-	-	-	-	-	-
5-9	0.1	0.1	0.0	0.1	0.1	-	-	-	-
10-14	0.1	0.1	0.1	0.1	0.1	0.0	0.1	-	-
15-19	0.2	0.3	0.1	0.2	0.2	0.1	0.2	0.3	-
20-24	0.3	0.4	0.2	0.3	0.4	0.2	0.4	0.5	0.3
25-29	0.4	0.6	0.3	0.4	0.5	0.3	0.8	1.1	0.5
30-34	0.6	0.8	0.4	0.6	0.7	0.4	0.9	1.2	0.6
35-39	0.8	1.1	0.6	0.8	1.0	0.6	1.3	1.7	0.9
40-44	1.3	1.8	0.9	1.3	1.7	0.8	2.2	2.7	1.7
45-49	2.2	2.9	1.6	2.2	2.9	1.5	2.9	3.6	2.4
50-54	3.7	4.9	2.5	3.6	4.8	2.5	4.7	6.5	3.2
55-59	6.4	8.4	4.5	6.5	8.5	4.6	6.7	9.1	4.6
60-64	10.5	13.5	7.7	10.8	13.9	7.9	9.8	13.3	7.0
65-69	17.1	21.8	13.0	17.9	22.7	13.5	13.7	17.1	11.1
70-74	26.9	33.7	21.1	28.4	35.4	22.4	17.9	23.4	14.1
75-79	42.5	53.2	34.3	44.9	56.0	36.2	24.7	30.9	20.8
80-84	60.3	77.2	49.1	63.6	81.0	51.9	31.0	41.5	25.4
85+	78.6	103.4	66.8	83.1	108.8	70.7	34.0	44.3	30.0

^a SEER 18 areas. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130), unless noted.

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130), unless noted.

- Rates are per 100,000 and are age-adjusted to the IARC world standard population.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.8
Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	31	31	31	-	-	-
1970-1973 ^a	-	-	-	41	39	43	-	-	-
1975-1977 ^b	46.5	45.5	47.5	46.8	46.3	47.3	48.4	42.6	54.8 ^g
1978-1980 ^b	47.9	46.1	49.8	47.9	46.2	49.5	51.1	46.9	56.7
1981-1983 ^b	50.5	50.2	50.9	50.8	50.5	51.1	49.4	49.0	49.8
1984-1986 ^b	51.6	50.0	53.3	52.0	50.6	53.6	46.7	44.5	49.6
1987-1989 ^b	50.9	47.6	54.9	51.3	48.1	55.3	46.1	41.7	51.2
1990-1992 ^b	50.7	46.7	55.8	51.6	47.6	56.5	42.0	38.1	47.5
1993-1995 ^b	52.5	48.7	57.4	53.2	49.7	57.6	42.0	35.9	53.7
1996-1998 ^b	58.9	57.0	61.0	59.5	57.6	61.6	54.2	52.7	56.4
1999-2003 ^b	66.3	64.2	68.7	67.4	65.7	69.4	59.0	54.0	64.9
2004-2010 ^b	71.4 ^f	70.1 ^f	72.8 ^f	72.5 ^f	71.5 ^f	73.6 ^f	63.0 ^f	58.8 ^f	67.7 ^f
5-Year Period Survival (Percent) ^{cd}									
2010	70.4	69.1	71.9	70.7	69.6	72.1	64.7	61.4	68.7
Stage Distribution (%) 2004-2010 ^{ee}									
All Stages									
Number of cases	92,653	49,978	42,675	77,541	41,843	35,698	7,475	4,057	3,418
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	28	27	29	28	27	29	28	25	31
Regional	15	15	16	15	15	16	15	14	15
Distant	49	51	47	50	51	48	51	54	47
Unstaged	8	7	8	7	7	8	7	6	7
5-Year Relative Survival (Percent), 2004-2010 ^c									
Age at Diagnosis:									
Ages <45	79.4	76.7	83.6	81.4	78.7	86.0	65.9	62.7	70.8
Ages 45-54	77.8	74.5	82.6	79.6	76.4	84.3	63.0	58.5	70.0
Ages 55-64	75.2	72.3	79.0	76.3	73.6	79.8	65.0	59.8	71.7
Ages 65-74	70.3	67.4	73.5	70.9	68.2	73.9	63.6	53.8	71.3
Ages 75+	53.1	52.3	53.7	53.7	52.8	54.4	44.9	44.8	44.4
Ages <65	77.2	74.3	81.3	78.6	75.9	82.6	64.8	60.6	70.9
Ages 65+	60.9	59.8	62.0	61.4	60.3	62.3	55.5	50.6	58.7
Stage ^e :									
All Stages	69.3	68.0	70.9	69.9	68.9	71.2	62.2	58.4	66.6
Localized	81.6	81.3	82.0	82.1	82.1	82.1	76.3	72.4	80.0
Regional	72.9	72.3	73.5	73.5	73.4	73.6	67.2	63.9	70.4
Distant	61.6	60.1	63.6	62.7	61.2	64.5	53.2	50.6	56.7
Unstaged	66.9	66.0	67.8	65.6	64.8	66.5	61.0	56.7	65.3

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2011.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
Based on follow-up of patients into 2011.

^d Period survival provides a 2010 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2007-2009: 0-1 year survival), (2006-2008: 1-2 year survival), (2005-2007: 2-3 year survival), (2004-2006: 3-4 year survival), (2003-2005: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2004-2010 is statistically significant (p<.05).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 19.9
Non-Hodgkin Lymphoma

SEER^a Relative Survival (Percent)
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Survival Time																				
1-year	70.2	73.0	71.3	70.4	70.3	73.2	75.7	76.7	77.3	77.2	78.7	81.0	80.3	81.0	81.5	80.9	81.5	83.9	83.7	83.9
2-year	60.2	63.7	62.8	62.2	61.7	65.8	68.5	70.0	71.0	71.3	73.3	76.0	75.7	76.0	77.1	76.8	77.3	78.7	79.1	
3-year	54.6	58.5	58.2	57.7	57.4	62.0	64.9	66.4	66.8	67.7	70.1	73.1	73.1	73.5	74.6	74.4	74.7	75.8		
4-year	50.5	54.5	54.3	54.4	54.6	58.6	62.1	63.6	64.4	65.4	68.1	71.2	71.6	71.4	72.7	72.5	72.8			
5-year	46.8	50.7	51.0	51.6	51.9	56.0	59.4	61.0	62.0	63.7	66.0	69.3	70.0	70.0	71.3	70.3				
6-year	43.6	47.5	48.3	49.2	49.8	54.1	57.1	58.4	59.5	61.9	64.7	68.1	68.3	68.6	69.9					
7-year	40.8	45.0	45.8	46.9	47.8	52.2	55.2	56.5	57.7	60.3	62.9	66.2	67.0	66.9						
8-year	38.4	42.8	43.4	45.0	46.3	50.4	52.9	55.3	56.2	58.7	61.3	65.0	65.6							
9-year	36.5	40.8	41.4	43.4	45.2	49.3	51.5	53.6	54.7	57.3	59.9	63.9								
10-year	34.9	38.9	39.8	42.1	44.2	48.1	50.1	52.3	53.5	56.0	58.8									
11-year	33.4	37.3	38.4	40.6	43.3	46.6	48.7	51.1	52.4	54.4										
12-year	32.3	35.9	36.8	39.5	42.1	45.5	48.1	50.2	51.0											
13-year	31.3	34.7	35.7	38.3	41.3	44.7	46.8	49.2												
14-year	30.1	33.5	34.6	37.1	40.4	44.1	45.4													
15-year	28.8	32.2	33.5	36.4	39.6	43.5														
16-year	27.8	31.1	32.7	35.5	39.0															
17-year	27.3	30.3	32.0	34.8																
18-year	26.6	29.5	31.3																	
19-year	25.9	28.7	30.5																	
20-year	25.1	27.9	30.0																	

^a Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 19.10
Non-Hodgkin Lymphoma

SEER^a Relative Survival (Percent)
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Survival Time																				
1-year	69.4	72.7	68.9	67.1	66.6	71.1	74.7	74.9	75.8	76.4	77.6	80.6	79.6	80.1	80.9	80.9	81.3	83.4	82.5	83.4
2-year	59.4	63.7	60.4	58.2	58.3	63.5	67.2	68.2	69.1	70.1	71.2	75.2	74.9	75.4	76.0	76.4	77.6	77.6	77.7	
3-year	53.3	58.0	55.7	53.7	54.5	59.7	63.8	64.5	64.3	66.6	67.9	71.9	72.5	72.5	72.9	73.5	75.2	74.8		
4-year	49.3	53.9	51.5	50.4	51.5	56.1	61.0	62.0	61.5	63.7	65.6	70.0	70.8	70.0	70.8	71.2	73.1			
5-year	45.4	50.1	48.2	47.6	48.5	53.6	58.2	59.2	59.0	61.5	63.5	67.9	68.9	68.7	69.6	68.8				
6-year	42.5	46.6	45.4	45.5	46.8	51.0	56.1	56.5	56.2	60.0	62.0	66.7	66.8	67.4	68.1					
7-year	39.9	44.2	43.1	43.6	44.8	49.1	54.2	54.5	54.6	58.5	60.0	65.2	65.6	65.3						
8-year	37.7	42.0	40.9	41.7	43.2	47.4	52.0	53.4	53.5	56.4	58.1	63.6	64.3							
9-year	35.6	40.1	39.0	40.2	42.3	46.5	50.4	51.5	52.3	55.0	57.1	62.7								
10-year	33.9	38.0	37.6	39.1	41.5	45.5	48.9	50.4	51.5	53.9	55.8									
11-year	32.7	36.3	36.3	38.0	40.7	43.7	47.6	49.5	50.7	52.4										
12-year	31.8	35.2	35.0	37.2	39.4	42.6	47.1	48.2	49.7											
13-year	30.6	34.2	34.1	36.1	38.8	41.8	45.5	46.9												
14-year	29.4	33.0	33.1	34.9	37.7	41.3	44.2													
15-year	28.0	31.9	32.3	34.3	36.7	40.8														
16-year	27.0	30.7	31.5	33.2	35.9															
17-year	26.4	29.9	30.7	32.5																
18-year	26.0	29.3	30.1																	
19-year	25.4	28.7	29.3																	
20-year	24.9	27.9	29.0																	

^a Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 19.11
Non-Hodgkin Lymphoma

SEER^a Relative Survival (Percent)
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Survival Time																				
1-year	71.0	73.3	74.1	74.7	75.1	75.8	76.8	78.7	79.1	78.1	80.1	81.4	81.0	82.1	82.3	80.9	81.8	84.5	85.1	84.7
2-year	61.1	63.7	65.6	67.2	66.3	68.7	70.1	72.0	73.2	72.6	75.8	76.9	76.6	76.7	78.4	77.3	76.9	80.1	80.8	
3-year	55.9	58.9	61.1	62.8	61.4	64.9	66.2	68.5	69.9	69.1	72.8	74.4	73.7	74.6	76.7	75.5	74.2	77.0		
4-year	51.9	55.2	57.6	59.5	58.8	61.8	63.4	65.4	68.0	67.4	71.1	72.5	72.4	73.0	74.9	73.8	72.4			
5-year	48.2	51.3	54.3	56.7	56.3	59.0	60.8	63.0	65.7	66.4	68.9	70.9	71.3	71.5	73.2	72.2				
6-year	44.6	48.4	51.7	53.9	53.8	58.0	58.4	60.5	63.3	64.3	68.0	69.6	69.9	69.9	72.1					
7-year	41.7	45.8	49.0	51.1	51.8	56.0	56.4	58.7	61.3	62.5	66.4	67.3	68.6	68.8						
8-year	39.2	43.7	46.3	49.1	50.4	54.1	54.0	57.4	59.4	61.4	65.0	66.7	67.0							
9-year	37.4	41.6	44.3	47.6	49.1	52.9	52.9	55.9	57.6	60.1	63.3	65.2								
10-year	36.0	39.8	42.4	45.8	47.8	51.3	51.7	54.4	55.9	58.5	62.3									
11-year	34.2	38.5	40.9	43.8	46.6	50.1	50.1	52.9	54.4	56.8										
12-year	32.8	36.7	39.0	42.5	45.7	49.2	49.3	52.3	52.5											
13-year	32.1	35.2	37.5	41.1	44.6	48.3	48.3	51.7												
14-year	30.9	34.0	36.5	40.0	43.9	47.6	46.7													
15-year	29.6	32.5	34.9	39.1	43.2	46.7														
16-year	28.7	31.5	34.2	38.5	42.9															
17-year	28.1	30.6	33.6	37.7																
18-year	27.3	29.7	32.7																	
19-year	26.4	28.7	32.0																	
20-year	25.3	27.9	31.1																	

^a Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 19.12

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2011

All Races, Males, All Ages

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011
SEER 9 ^b	5,222	2,506	2,704	3,174	3,627	3,990	4,569	4,729	5,325	5,253	5,259	5,540	5,762	6,218	6,360	6,635	6,910
SEER 9 except SF-Oakland	4,284	2,088	2,267	2,601	2,818	3,088	3,506	3,695	4,158	4,243	4,360	4,493	4,809	5,200	5,363	5,570	5,766
San Francisco-Oakland SMSA ^c	938	418	437	573	809	902	1,063	1,034	1,167	1,010	899	1,047	953	1,018	997	1,065	1,144
San Francisco City/County	245	96	123	210	326	393	467	410	451	353	213	256	219	282	218	214	240

Age-Adjusted Cancer Incidence Rates^a

By SEER Location and Year of Diagnosis, 1975-2011

All Races, Males, All Ages

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011
SEER 9 ^b	13.4	15.5	16.1	18.3	20.1	21.5	23.4	23.2	25.2	24.4	23.8	24.3	24.6	25.7	25.3	25.2	25.2
SEER 9 except SF-Oakland	13.2	15.4	16.1	18.1	18.8	20.0	21.7	21.8	23.6	23.5	23.5	23.5	24.4	25.6	25.3	25.1	24.9
San Francisco-Oakland SMSA ^c	14.8	15.8	16.0	19.4	26.8	28.4	31.7	30.5	33.5	28.8	25.2	28.6	25.4	26.6	25.5	26.0	26.5
San Francisco City/County	14.3	14.4	17.6	29.3	44.4	51.9	61.0	52.3	57.5	44.6	27.4	32.5	26.8	35.3	26.4	25.4	27.3

^a Rates are per 100,000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).^b The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.^c The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.13

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2011

All Races, Males, Ages 0-19

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011
SEER 9 ^b	223	88	108	90	94	85	100	89	119	105	104	119	127	106	104	143	133
SEER 9 except SF-Oakland	191	79	95	81	80	77	86	74	106	84	93	100	115	89	85	114	118
San Francisco- Oakland SMSA ^c	32	9	13	9	14	8	14	15	13	21	11	19	12	17	19	29	15
San Francisco City/County	9	<4	<4	<4	<4	<4	<4	<4	<4	<4	<4	<4	<4	<4	<4	5	<4

Age-Adjusted Cancer Incidence Rates^a

By SEER Location and Year of Diagnosis, 1975-2011

All Races, Males, Ages 0-19

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011
SEER 9 ^b	1.2	1.3	1.6	1.3	1.4	1.3	1.5	1.3	1.6	1.4	1.4	1.5	1.6	1.4	1.3	1.8	1.7
SEER 9 except SF-Oakland	1.2	1.3	1.6	1.4	1.4	1.3	1.5	1.2	1.7	1.3	1.4	1.5	1.7	1.3	1.2	1.6	1.7
San Francisco- Oakland SMSA ^c	1.4	1.0	1.5	1.0	1.6	0.9	1.5	1.6	1.3	2.1	1.1	1.8	1.2	1.7	1.9	2.8	1.4
San Francisco City/County	2.3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.0	-

^a Rates are per 100,000 males aged 0-19 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

^c The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.14

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2011

All Races, Males, Ages 20-54

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011
SEER 9 ^b	1,463	686	723	957	1,210	1,410	1,765	1,831	2,090	1,763	1,607	1,685	1,617	1,714	1,644	1,678	1,654
SEER 9 except SF-Oakland	1,207	562	588	729	826	921	1,194	1,295	1,484	1,319	1,268	1,316	1,303	1,402	1,373	1,388	1,386
San Francisco-Oakland SMSA ^c	256	124	135	228	384	489	571	536	606	444	339	369	314	312	271	290	268
San Francisco City/County	58	29	34	105	215	288	333	303	317	224	105	115	111	110	85	75	72

Age-Adjusted Cancer Incidence Rates^a

By SEER Location and Year of Diagnosis, 1975-2011

All Races, Males, Ages 20-54

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011
SEER 9 ^b	6.9	7.9	8.2	10.4	12.4	13.5	15.9	15.6	16.9	13.7	12.1	12.3	11.6	12.2	11.5	11.7	11.5
SEER 9 except SF-Oakland	6.9	7.8	8.1	9.7	10.3	10.8	13.1	13.4	14.4	12.3	11.5	11.5	11.2	11.9	11.4	11.5	11.4
San Francisco-Oakland SMSA ^c	6.9	8.4	8.9	13.9	22.6	26.4	29.5	26.7	29.8	21.2	15.6	16.4	13.9	14.1	12.2	12.9	11.6
San Francisco City/County	6.7	8.8	9.4	27.2	56.5	71.5	81.3	72.4	74.4	50.7	23.0	25.2	23.9	24.6	19.1	16.2	15.0

^a Rates are per 100,000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

^c The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.15

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2011

All Races, Males, Ages 55+

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011
SEER 9 ^b	3,536	1,732	1,873	2,127	2,323	2,495	2,704	2,809	3,116	3,385	3,548	3,736	4,018	4,398	4,612	4,814	5,123
SEER 9 except SF-Oakland	2,886	1,447	1,584	1,791	1,912	2,090	2,226	2,326	2,568	2,840	2,999	3,077	3,391	3,709	3,905	4,068	4,262
San Francisco-Oakland SMSA ^c	650	285	289	336	411	405	478	483	548	545	549	659	627	689	707	746	861
San Francisco City/County	178	65	88	104	109	105	132	106	131	126	106	141	107	169	131	134	165

Age-Adjusted Cancer Incidence Rates^a

By SEER Location and Year of Diagnosis, 1975-2011

All Races, Males, Ages 55+

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011
SEER 9 ^b	45.2	52.2	54.0	59.6	63.3	67.2	70.1	70.6	76.1	80.1	81.1	82.9	85.7	90.0	89.6	88.1	88.8
SEER 9 except SF-Oakland	44.0	52.1	54.4	60.1	62.0	66.7	68.7	69.2	74.3	79.7	81.3	81.0	85.7	90.1	89.9	88.2	87.6
San Francisco-Oakland SMSA ^c	50.9	52.8	52.0	57.1	70.3	70.3	77.3	78.2	85.5	82.1	79.9	93.1	85.1	89.5	88.2	87.9	95.0
San Francisco City/County	48.2	44.6	59.8	72.7	73.9	75.7	93.4	74.7	92.1	87.2	72.7	93.4	68.5	104.7	76.5	75.7	89.5

^a Rates are per 100,000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).^b The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.^c The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Non-Hodgkin Lymphoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 19.16
Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and
Lifetime Risk of Dying from Cancer Given Alive at Current Age
Both Sexes, 2009-2011 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.01	0.02	0.05	2.12	0.78	Asian/ Pacific Islander	0	0.01	0.02	0.04	1.83	0.74
	10	0.01	0.04	0.10	2.14	0.79		10	0.01	0.03	0.07	1.84	0.75
	20	0.03	0.09	0.21	2.13	0.79		20	0.02	0.06	0.13	1.83	0.75
	30	0.06	0.18	0.42	2.12	0.79		30	0.04	0.11	0.28	1.81	0.75
	40	0.12	0.36	0.82	2.09	0.79		40	0.07	0.24	0.57	1.78	0.75
	50	0.25	0.72	1.38	2.02	0.80		50	0.17	0.50	1.00	1.73	0.75
	60	0.50	1.20	1.75	1.88	0.80		60	0.34	0.86	1.41	1.61	0.74
	70	0.80	1.42	-	1.57	0.76		70	0.56	1.15	-	1.36	0.69
80	0.85	-	-	1.05	0.63	80	0.71	-	-	0.97	0.57		
White	0	0.01	0.02	0.05	2.22	0.82	American Indian/ Alaska Native ^a	0	0.01	0.02	0.04	1.33	0.50
	10	0.02	0.04	0.10	2.24	0.82		10	0.01	0.03	0.07	1.34	0.50
	20	0.03	0.09	0.21	2.23	0.83		20	0.02	0.06	0.13	1.34	0.50
	30	0.06	0.18	0.43	2.22	0.83		30	0.05	0.11	0.25	1.34	0.51
	40	0.13	0.37	0.86	2.19	0.83		40	0.07	0.21	0.53	1.32	0.52
	50	0.26	0.75	1.45	2.12	0.84		50	0.15	0.49	0.93	1.31	0.53
	60	0.52	1.27	1.84	1.97	0.84		60	0.36	0.83	1.15	1.24	0.55
	70	0.85	1.50	-	1.64	0.80		70	0.54	0.90	-	1.00	0.51
80	0.89	-	-	1.09	0.66	80	0.50	-	-	0.63	0.33		
Black	0	0.01	0.02	0.05	1.28	0.45	Hispanic ^b	0	0.01	0.02	0.04	2.23	0.77
	10	0.01	0.05	0.12	1.30	0.46		10	0.01	0.04	0.09	2.25	0.78
	20	0.04	0.11	0.23	1.29	0.46		20	0.03	0.07	0.18	2.24	0.78
	30	0.07	0.20	0.40	1.28	0.46		30	0.05	0.15	0.37	2.23	0.78
	40	0.13	0.34	0.65	1.23	0.46		40	0.11	0.33	0.76	2.20	0.78
	50	0.22	0.54	0.88	1.14	0.45		50	0.23	0.67	1.34	2.14	0.78
	60	0.36	0.73	0.95	1.02	0.43		60	0.46	1.17	1.79	2.00	0.76
	70	0.45	0.72	-	0.80	0.39		70	0.78	1.47	-	1.69	0.72
80	0.40	-	-	0.51	0.31	80	0.88	-	-	1.16	0.58		

Devcan 6.8.0, August 2014, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG). Mortality data are from the NCHS public use data file for the total US.

^a Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 19.17
Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and
Lifetime Risk of Dying from Cancer Given Alive at Current Age
Males, 2009-2011 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.01	0.03	0.06	2.36	0.87	Asian/ Pacific Islander	0	0.01	0.03	0.05	2.06	0.83
	10	0.02	0.05	0.13	2.38	0.88		10	0.02	0.04	0.08	2.06	0.84
	20	0.04	0.11	0.25	2.37	0.89		20	0.02	0.06	0.14	2.05	0.84
	30	0.07	0.22	0.49	2.37	0.89		30	0.04	0.12	0.30	2.04	0.84
	40	0.15	0.43	0.94	2.33	0.90		40	0.08	0.27	0.66	2.02	0.84
	50	0.29	0.82	1.57	2.26	0.91		50	0.19	0.58	1.20	1.97	0.84
	60	0.58	1.38	1.99	2.12	0.91		60	0.41	1.06	1.65	1.85	0.83
	70	0.94	1.65	-	1.81	0.87		70	0.70	1.35	-	1.57	0.78
80	1.02	-	-	1.26	0.75	80	0.82	-	-	1.10	0.67		
White	0	0.01	0.03	0.06	2.46	0.92	American Indian/ Alaska Native ^a	0	0.02	0.03	0.06	1.36	0.52
	10	0.02	0.06	0.13	2.48	0.93		10	0.02	0.04	0.08	1.36	0.52
	20	0.04	0.11	0.25	2.47	0.93		20	0.02	0.07	0.13	1.35	0.53
	30	0.07	0.22	0.50	2.46	0.94		30	0.05	0.10	0.21	1.36	0.53
	40	0.15	0.43	0.98	2.43	0.94		40	0.06	0.16	0.52	1.35	0.55
	50	0.30	0.86	1.65	2.36	0.95		50	0.11	0.48	1.04	1.35	0.57
	60	0.60	1.45	2.08	2.22	0.95		60	0.40	1.01	1.34	1.35	0.58
	70	0.99	1.73	-	1.89	0.92		70	0.72	1.11	-	1.12	0.51
80	1.07	-	-	1.30	0.78	80	0.56	-	-	0.58	0.24		
Black	0	0.01	0.03	0.07	1.41	0.51	Hispanic ^b	0	0.01	0.02	0.05	2.39	0.82
	10	0.02	0.06	0.15	1.43	0.52		10	0.02	0.05	0.10	2.41	0.82
	20	0.04	0.14	0.29	1.43	0.52		20	0.03	0.09	0.20	2.40	0.83
	30	0.09	0.26	0.51	1.41	0.52		30	0.06	0.17	0.42	2.39	0.83
	40	0.17	0.43	0.77	1.35	0.52		40	0.12	0.36	0.84	2.37	0.83
	50	0.27	0.63	0.98	1.24	0.51		50	0.25	0.75	1.49	2.31	0.83
	60	0.40	0.80	1.02	1.10	0.49		60	0.52	1.31	1.98	2.18	0.82
	70	0.50	0.78	-	0.88	0.46		70	0.90	1.65	-	1.87	0.77
80	0.46	-	-	0.62	0.37	80	1.01	-	-	1.31	0.61		

Devcan 6.8.0, August 2014, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG). Mortality data are from the NCHS public use data file for the total US.

^a Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 19.18
Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and
Lifetime Risk of Dying from Cancer Given Alive at Current Age
Females, 2009-2011 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.00	0.01	0.04	1.91	0.69	Asian/ Pacific Islander	0	0.01	0.01	0.03	1.64	0.67
	10	0.01	0.03	0.08	1.93	0.70		10	0.01	0.03	0.07	1.64	0.68
	20	0.02	0.07	0.17	1.92	0.70		20	0.02	0.06	0.13	1.64	0.68
	30	0.05	0.15	0.35	1.91	0.70		30	0.04	0.10	0.25	1.62	0.68
	40	0.10	0.30	0.70	1.88	0.70		40	0.07	0.21	0.49	1.59	0.68
	50	0.21	0.62	1.20	1.81	0.71		50	0.15	0.43	0.84	1.54	0.67
	60	0.43	1.04	1.55	1.68	0.70		60	0.29	0.71	1.22	1.42	0.66
	70	0.68	1.25	-	1.39	0.67		70	0.45	0.99	-	1.20	0.62
80	0.73	-	-	0.92	0.56	80	0.63	-	-	0.88	0.51		
White	0	0.00	0.02	0.04	2.01	0.73	American Indian/ Alaska Native ^a	0	0.00	0.01	0.02	1.31	0.47
	10	0.01	0.03	0.08	2.02	0.74		10	0.01	0.02	0.06	1.32	0.48
	20	0.02	0.07	0.17	2.01	0.74		20	0.01	0.06	0.13	1.31	0.48
	30	0.05	0.15	0.36	2.00	0.74		30	0.05	0.12	0.30	1.32	0.48
	40	0.10	0.31	0.74	1.97	0.74		40	0.07	0.26	0.55	1.29	0.48
	50	0.22	0.65	1.27	1.90	0.74		50	0.19	0.49	0.83	1.26	0.50
	60	0.45	1.11	1.64	1.76	0.74		60	0.32	0.67	0.98	1.13	0.51
	70	0.72	1.31	-	1.45	0.71		70	0.40	0.73	-	0.90	0.50
80	0.77	-	-	0.95	0.59	80	0.44	-	-	0.66	0.39		
Black	0	0.00	0.01	0.04	1.17	0.40	Hispanic ^b	0	0.01	0.01	0.03	2.10	0.73
	10	0.01	0.04	0.09	1.19	0.41		10	0.01	0.03	0.07	2.11	0.74
	20	0.03	0.08	0.18	1.18	0.41		20	0.02	0.06	0.16	2.10	0.74
	30	0.06	0.15	0.31	1.16	0.41		30	0.04	0.14	0.33	2.09	0.74
	40	0.09	0.25	0.54	1.12	0.40		40	0.10	0.29	0.68	2.06	0.74
	50	0.17	0.46	0.79	1.06	0.40		50	0.20	0.60	1.21	1.99	0.73
	60	0.32	0.68	0.90	0.97	0.39		60	0.41	1.05	1.64	1.85	0.72
	70	0.42	0.68	-	0.76	0.35		70	0.69	1.33	-	1.56	0.68
80	0.36	-	-	0.46	0.27	80	0.78	-	-	1.06	0.55		

Devcan 6.8.0, August 2014, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG). Mortality data are from the NCHS public use data file for the total US.

^a Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 19.19
Non-Hodgkin Lymphoma

SEER Incidence and U.S. Mortality
Age-Adjusted Rates and Trends^a
By Race/Ethnicity and Sex

SEER Incidence	SEER 18 Areas ^b			SEER 13 Areas ^b			SEER 9 Areas ^b		
	Rate 2007-2011			Trend 2002-2011 ^c			Trend 2002-2011 ^d		
	Rate per 100,000 persons			AAPC (%)			AAPC (%)		
RACE/ETHNICITY	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Races	19.7	23.9	16.3	0.3*	0.2	-0.3	0.5*	0.3*	-0.4
White	20.6	24.9	17.2	-0.3	-0.1	-0.3	-0.3	0.4*	-0.5
White Hispanic ^e	18.4	21.4	16.0	0.5*	0.3	0.9*	-	-	-
White Non-Hispanic ^e	21.1	25.5	17.4	-0.4	-0.2	-0.4	-	-	-
Black	14.3	17.4	11.9	0.5*	-0.2	0.3	0.3	-0.4	-0.5
Asian/Pacific Islander	13.4	16.3	11.2	0.3	0.2	0.4	-	-	-
Amer Ind/Alaska Nat ^f	12.2	14.1	10.6	2.4*	-	-	-	-	-
Hispanic ^e	17.7	20.6	15.4	0.5*	0.3	0.9*	-	-	-
<u>U.S. Mortality^g</u>									
	Rate 2007-2011			Trend 2002-2011 ^h					
	Rate per 100,000 persons			AAPC (%)					
RACE/ETHNICITY	Total	Males	Females	Total	Males	Females			
All Races	6.3	8.1	5.0	-2.6*	-2.3*	-3.1*			
White	6.6	8.4	5.2	-2.6*	-2.6*	-3.0*			
White Hispanic ^e	5.6	6.8	4.6	-1.2*	-1.7*	-1.9*			
White Non-Hispanic ^e	6.6	8.5	5.2	-2.6*	-2.6*	-3.2*			
Black	4.5	5.8	3.5	-2.5*	-2.4*	-2.5*			
Asian/Pacific Islander	4.1	5.2	3.4	-2.0*	-2.2*	-1.6*			
Amer Ind/Alaska Nat									
Total U.S.	3.4	3.9	2.8	-3.8*	-3.3*	-5.5*			
CHSDA Counties	4.6	5.3	3.9	-0.4	-0.6	-0.3			
Non-CHSDA Counties	1.9	2.4	1.5	-7.7*	-	-			
Hispanic ^e	5.3	6.4	4.4	-1.4*	-2.3*	-2.1*			

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 4.1.0, April 2014, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

b The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta.

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry, and Rural Georgia.

The SEER 18 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG.

c The 2002-2011 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints over diagnosis years 1992-2011.

d The 2002-2011 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints over diagnosis years 1975-2011.

e Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2002-2011 Hispanic and Non-Hispanic mortality trends exclude deaths from New Hampshire and Oklahoma.

f Incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

g US Mortality Files, National Center for Health Statistics, CDC.

h The 2002-2011 mortality AAPCs are based on a Joinpoint analysis using years of death 1992-2011.

* The APC is significantly different from zero (p<.05).

Table 19.20
Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Rates^a
By Registry, Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Incidence Rates^a, 2007-2011</u>									
California	18.89	22.96	15.55	19.89	24.11	16.35	13.81	16.47	11.55
Greater Bay Area	20.66	25.82	16.34	23.02	28.94	17.82	15.45	17.60	13.64
San Francisco-Oakland	20.72	26.58	15.93	23.14	29.97	17.25	15.27	17.50	13.42
San Jose-Monterey	20.60	24.42	17.20	22.85	27.17	18.86	17.79	19.64	16.24
Los Angeles	18.56	22.57	15.36	20.10	24.35	16.62	14.19	17.50	11.64
Greater California	18.42	22.13	15.36	18.92	22.62	15.84	12.62	14.99	10.39
Connecticut	20.84	25.29	17.36	21.06	25.54	17.54	13.73	15.36	12.31
Detroit	21.42	25.79	18.05	23.04	27.35	19.67	15.57	19.90	12.46
Georgia	18.01	22.10	14.77	19.17	23.18	15.87	14.18	17.84	11.57
Atlanta	19.25	24.42	15.40	20.87	26.40	16.53	16.65	20.51	13.88
Rural Georgia	16.32	20.07	13.01	19.78	21.50	17.62	9.28	-	-
Greater Georgia	17.39	21.04	14.43	18.54	22.06	15.57	12.51	15.86	10.07
Hawaii	17.59	21.32	14.43	20.67	25.27	15.98	-	-	-
Iowa	22.40	27.02	18.74	22.27	26.83	18.68	19.57	26.30	13.76
Kentucky	20.62	24.88	17.24	20.79	24.92	17.51	15.18	20.29	11.34
Louisiana	20.04	24.29	16.61	21.92	26.42	18.15	14.35	17.10	12.17
New Jersey	21.07	25.14	17.90	22.10	26.24	18.83	14.07	16.56	12.13
New Mexico	15.46	17.90	13.36	15.42	17.80	13.37	12.24	16.45	-
Seattle-Puget Sound	22.70	27.53	18.68	23.30	28.22	19.17	16.38	17.42	14.74
Utah	19.88	24.88	15.65	20.11	25.26	15.76	19.17	-	-
9 SEER Areas ^b	20.66	25.33	16.89	21.61	26.42	17.66	15.77	19.14	13.15
11 SEER Areas ^b	20.18	24.66	16.56	21.35	26.04	17.49	15.45	18.77	12.87
13 SEER Areas ^b	20.15	24.62	16.54	21.35	26.02	17.49	15.38	18.73	12.78
18 SEER Areas ^b	19.68	23.86	16.32	20.64	24.90	17.15	14.33	17.41	11.92

^a Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

^b The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

The SEER 11 areas comprise the SEER 9 areas plus San Jose-Monterey and Los Angeles.

The SEER 13 areas comprise the SEER 11 areas plus the Alaska Native Registry and Rural Georgia.

The SEER 18 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.21
Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Rates^a
By Registry, Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Death Rates^a, 2007-2011</u>									
California	6.03	7.73	4.73	6.42	8.27	4.97	4.76	6.00	3.86
Greater Bay Area	6.16	8.07	4.70	6.82	9.07	5.04	5.40	6.69	4.69
San Francisco-Oakland	6.01	8.09	4.44	6.62	9.13	4.65	5.49	6.36	5.06
San Jose-Monterey	6.43	8.01	5.19	7.17	8.96	5.73	-	-	-
Los Angeles	5.78	7.31	4.62	6.22	7.89	4.94	5.10	6.33	4.14
Greater California	6.10	7.79	4.79	6.37	8.18	4.96	3.97	5.30	2.91
Connecticut	5.85	7.32	4.78	5.95	7.45	4.83	4.00	5.01	3.41
Detroit	6.77	8.58	5.50	7.31	9.03	6.12	4.83	7.01	3.35
Georgia	5.63	7.51	4.31	6.11	7.93	4.80	3.95	5.81	2.76
Atlanta	5.42	7.68	4.03	5.93	8.25	4.43	4.25	6.56	3.04
Rural Georgia	5.93	8.77	4.11	7.24	9.29	6.03	-	-	-
Greater Georgia	5.71	7.41	4.43	6.15	7.78	4.91	3.83	5.40	2.66
Hawaii	5.62	7.42	4.27	6.13	8.33	4.18	-	-	-
Iowa	6.81	8.85	5.30	6.81	8.87	5.30	-	-	-
Kentucky	6.99	8.60	5.79	7.15	8.66	6.01	4.67	7.90	2.53
Louisiana	6.57	8.64	4.96	7.20	9.31	5.52	4.44	5.99	3.24
New Jersey	6.00	7.48	4.97	6.35	7.89	5.25	4.17	5.47	3.38
New Mexico	5.19	6.21	4.30	5.36	6.44	4.40	-	-	-
Seattle-Puget Sound	6.73	8.82	5.09	7.01	9.19	5.28	3.98	4.42	-
Utah	5.81	7.32	4.57	5.87	7.39	4.63	-	-	-
9 SEER Areas ^b	6.18	8.00	4.82	6.49	8.37	5.06	4.60	6.29	3.49
11 SEER Areas ^b	6.11	7.85	4.80	6.48	8.31	5.08	4.73	6.31	3.66
13 SEER Areas ^b	6.11	7.85	4.79	6.49	8.32	5.08	4.69	6.31	3.60
18 SEER Areas ^b	6.14	7.86	4.85	6.50	8.28	5.14	4.39	5.98	3.29
Total U.S.	6.29	8.07	4.95	6.55	8.38	5.16	4.45	5.80	3.50

^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta. The SEER 11 areas comprise the SEER 9 areas plus San Jose-Monterey and Los Angeles.

The SEER 13 areas comprise the SEER 11 areas plus the Alaska Native Registry and Rural Georgia.

The SEER 18 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG.

- Statistic not shown. Rate based on less than 16 cases for the time interval.


Table 19.22
Non-Hodgkin Lymphoma

Age-Adjusted Cancer Death^a Rates By State, All Races, 2007-2011

Males and Females

State	Rate	SE	Rank	PD
TOTAL U.S.	6.29	0.02		
High Five States				
West Virginia	7.17 ^b	0.25	(01)	14.07
Ohio	7.08 ^b	0.10	(02)	12.66
Minnesota	7.04 ^b	0.16	(03)	11.98
Kentucky	6.99 ^b	0.18	(04)	11.12
Michigan	6.98 ^b	0.11	(05)	11.05
Low Five States				
Hawaii	5.62	0.27	(47)	-10.56
Nevada	5.58	0.22	(48)	-11.19
North Dakota	5.54	0.38	(49)	-11.89
New Mexico	5.19 ^b	0.22	(50)	-17.38 ^c
D.C.	5.03	0.42	(51)	-20.01 ^c

State	Rate	SE	Rank	PD	State	Rate	SE	Rank	PD
Alabama	6.43	0.16	(22)	2.31	Montana	6.00	0.32	(31)	-4.62
Alaska	6.30	0.57	(23)	0.18	Nebraska	6.74	0.26	(15)	7.16
Arizona	5.93	0.13	(37)	-5.67	Nevada	5.58	0.22	(48)	-11.19
Arkansas	6.78	0.21	(13)	7.80	New Hampshire	5.78	0.28	(42)	-8.00
California	6.03 ^b	0.06	(28)	-4.15	New Jersey	6.00	0.11	(32)	-4.64
Colorado	5.68 ^b	0.16	(45)	-9.69	New Mexico	5.19 ^b	0.22	(50)	-17.38 ^c
Connecticut	5.85	0.17	(40)	-6.89	New York	5.99 ^b	0.08	(33)	-4.78
Delaware	6.00	0.35	(30)	-4.52	North Carolina	5.95	0.11	(36)	-5.40
D.C.	5.03	0.42	(51)	-20.01 ^c	North Dakota	5.54	0.38	(49)	-11.89
Florida	5.95 ^b	0.07	(35)	-5.30	Ohio	7.08 ^b	0.10	(02)	12.66
Georgia	5.63 ^b	0.12	(46)	-10.54	Oklahoma	6.96 ^b	0.19	(06)	10.77
Hawaii	5.62	0.27	(47)	-10.56	Oregon	6.48	0.18	(20)	3.07
Idaho	6.52	0.30	(19)	3.70	Pennsylvania	6.86 ^b	0.09	(10)	9.15
Illinois	6.45	0.10	(21)	2.51	Rhode Island	5.70	0.31	(44)	-9.38
Indiana	6.95 ^b	0.14	(07)	10.51	South Carolina	5.87	0.16	(38)	-6.71
Iowa	6.81	0.19	(12)	8.23	South Dakota	6.24	0.36	(25)	-0.71
Kansas	6.93	0.21	(08)	10.29	Tennessee	6.76	0.14	(14)	7.51
Kentucky	6.99 ^b	0.18	(04)	11.12	Texas	6.02 ^b	0.08	(29)	-4.21
Louisiana	6.57	0.17	(17)	4.56	Utah	5.81	0.24	(41)	-7.66
Maine	6.89	0.29	(09)	9.54	Vermont	6.28	0.42	(24)	-0.18
Maryland	5.75 ^b	0.14	(43)	-8.60	Virginia	6.16	0.13	(26)	-2.05
Massachusetts	5.86	0.13	(39)	-6.87	Washington	6.63	0.14	(16)	5.52
Michigan	6.98 ^b	0.11	(05)	11.05	West Virginia	7.17 ^b	0.25	(01)	14.07
Minnesota	7.04 ^b	0.16	(03)	11.98	Wisconsin	6.82 ^b	0.15	(11)	8.46
Mississippi	5.99	0.20	(34)	-4.80	Wyoming	6.11	0.48	(27)	-2.85
Missouri	6.55	0.14	(18)	4.10					



^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
^b Difference between state rate and total U.S. rate is statistically significant ($p \leq .0002$).
^c Absolute percent difference between state rate and total U.S. rate is 15% or more.
SE Standard error of the rate.
PD Percent difference between state rate and total U.S. rate.
- Statistic not shown. Rate based on less than 16 cases for the time interval.


Table 19.23
Non-Hodgkin Lymphoma

Age-Adjusted Cancer Death^a Rates By State, All Races, 2007-2011

Males

State	Rate	SE	Rank	PD
TOTAL U.S.	8.07	0.03		
High Five States				
Minnesota	9.39 ^b	0.29	(01)	16.38 ^c
Ohio	9.19 ^b	0.19	(02)	13.92
Kansas	9.18	0.38	(03)	13.72
Maine	9.11	0.52	(04)	12.91
Indiana	9.07 ^b	0.26	(05)	12.36
Low Five States				
Wyoming	7.31	0.81	(47)	-9.35
Nevada	6.91	0.36	(48)	-14.35
North Dakota	6.70	0.63	(49)	-16.98 ^c
D.C.	6.49	0.76	(50)	-19.59 ^c
New Mexico	6.21 ^b	0.37	(51)	-23.06 ^c

State	Rate	SE	Rank	PD	State	Rate	SE	Rank	PD
Alabama	8.21	0.29	(22)	1.79	Montana	7.78	0.55	(28)	-3.54
Alaska	8.18	0.98	(24)	1.31	Nebraska	8.30	0.44	(19)	2.91
Arizona	7.32	0.22	(46)	-9.33	Nevada	6.91	0.36	(48)	-14.35
Arkansas	8.34	0.35	(17)	3.41	New Hampshire	7.40	0.50	(43)	-8.30
California	7.73	0.10	(30)	-4.26	New Jersey	7.48	0.20	(39)	-7.27
Colorado	7.41	0.29	(42)	-8.15	New Mexico	6.21 ^b	0.37	(51)	-23.06 ^c
Connecticut	7.32	0.29	(45)	-9.31	New York	7.71	0.13	(31)	-4.45
Delaware	7.45	0.60	(40)	-7.70	North Carolina	7.48	0.20	(38)	-7.24
D.C.	6.49	0.76	(50)	-19.59 ^c	North Dakota	6.70	0.63	(49)	-16.98 ^c
Florida	7.57 ^b	0.12	(35)	-6.23	Ohio	9.19 ^b	0.19	(02)	13.92
Georgia	7.51	0.22	(36)	-6.95	Oklahoma	8.83	0.33	(10)	9.41
Hawaii	7.42	0.47	(41)	-8.01	Oregon	8.38	0.30	(16)	3.79
Idaho	7.84	0.49	(26)	-2.83	Pennsylvania	8.85 ^b	0.17	(08)	9.71
Illinois	8.30	0.18	(20)	2.84	Rhode Island	7.75	0.56	(29)	-4.00
Indiana	9.07 ^b	0.26	(05)	12.36	South Carolina	7.70	0.29	(32)	-4.63
Iowa	8.85	0.34	(09)	9.66	South Dakota	7.63	0.61	(34)	-5.39
Kansas	9.18	0.38	(03)	13.72	Tennessee	8.92	0.26	(06)	10.52
Kentucky	8.60	0.31	(13)	6.54	Texas	7.79	0.14	(27)	-3.45
Louisiana	8.64	0.31	(12)	7.12	Utah	7.32	0.41	(44)	-9.29
Maine	9.11	0.52	(04)	12.91	Vermont	8.34	0.75	(18)	3.30
Maryland	7.49	0.25	(37)	-7.23	Virginia	8.19	0.23	(23)	1.49
Massachusetts	7.68	0.23	(33)	-4.85	Washington	8.56	0.25	(14)	6.04
Michigan	8.89 ^b	0.20	(07)	10.19	West Virginia	8.43	0.42	(15)	4.48
Minnesota	9.39 ^b	0.29	(01)	16.38 ^c	Wisconsin	8.73	0.26	(11)	8.25
Mississippi	7.96	0.37	(25)	-1.35	Wyoming	7.31	0.81	(47)	-9.35
Missouri	8.27	0.25	(21)	2.52					



^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
^b Difference between state rate and total U.S. rate is statistically significant (p<=.0002).
^c Absolute percent difference between state rate and total U.S. rate is 15% or more.
SE Standard error of the rate.
PD Percent difference between state rate and total U.S. rate.
- Statistic not shown. Rate based on less than 16 cases for the time interval.



Table 19.24
Non-Hodgkin Lymphoma

Age-Adjusted Cancer Death^a Rates By State, All Races, 2007-2011

Females

State	Rate	SE	Rank	PD
TOTAL U.S.	4.95	0.02		
High Five States				
West Virginia	6.19 ^b	0.31	(01)	25.05 ^c
Kentucky	5.79 ^b	0.21	(02)	16.88 ^c
Arkansas	5.62	0.25	(03)	13.45
Oklahoma	5.56	0.22	(04)	12.28
Michigan	5.56 ^b	0.13	(05)	12.23
Low Five States				
Georgia	4.31 ^b	0.14	(47)	-13.00
New Mexico	4.30	0.27	(48)	-13.06
Hawaii	4.27	0.32	(49)	-13.81
Rhode Island	4.23	0.34	(50)	-14.59
D.C.	3.94	0.49	(51)	-20.48 ^c

State	Rate	SE	Rank	PD	State	Rate	SE	Rank	PD
Alabama	5.15	0.19	(18)	4.06	Montana	4.51	0.38	(43)	-8.88
Alaska	4.70	0.67	(32)	-5.13	Nebraska	5.53	0.31	(06)	11.78
Arizona	4.80	0.16	(26)	-3.02	Nevada	4.42	0.27	(45)	-10.61
Arkansas	5.62	0.25	(03)	13.45	New Hampshire	4.56	0.34	(41)	-7.84
California	4.73	0.07	(31)	-4.50	New Jersey	4.97	0.13	(24)	0.31
Colorado	4.33	0.19	(46)	-12.58	New Mexico	4.30	0.27	(48)	-13.06
Connecticut	4.78	0.20	(29)	-3.50	New York	4.76	0.09	(30)	-3.76
Delaware	4.79	0.42	(28)	-3.23	North Carolina	4.80	0.13	(27)	-3.11
D.C.	3.94	0.49	(51)	-20.48 ^c	North Dakota	4.61	0.46	(37)	-6.79
Florida	4.63 ^b	0.08	(36)	-6.36	Ohio	5.53 ^b	0.12	(07)	11.71
Georgia	4.31 ^b	0.14	(47)	-13.00	Oklahoma	5.56	0.22	(04)	12.28
Hawaii	4.27	0.32	(49)	-13.81	Oregon	5.03	0.21	(23)	1.68
Idaho	5.44	0.37	(08)	9.83	Pennsylvania	5.39 ^b	0.11	(11)	8.89
Illinois	5.15	0.12	(19)	4.01	Rhode Island	4.23	0.34	(50)	-14.59
Indiana	5.41	0.17	(09)	9.19	South Carolina	4.59	0.18	(39)	-7.34
Iowa	5.30	0.23	(13)	6.99	South Dakota	5.14	0.44	(20)	3.75
Kansas	5.21	0.25	(17)	5.25	Tennessee	5.13	0.16	(21)	3.63
Kentucky	5.79 ^b	0.21	(02)	16.88 ^c	Texas	4.69	0.09	(33)	-5.30
Louisiana	4.96	0.20	(25)	0.26	Utah	4.57	0.29	(40)	-7.64
Maine	5.25	0.34	(15)	6.06	Vermont	4.66	0.48	(34)	-5.78
Maryland	4.46	0.17	(44)	-9.85	Virginia	4.66	0.14	(35)	-5.83
Massachusetts	4.60	0.15	(38)	-7.16	Washington	5.13	0.17	(22)	3.57
Michigan	5.56 ^b	0.13	(05)	12.23	West Virginia	6.19 ^b	0.31	(01)	25.05 ^c
Minnesota	5.24	0.18	(16)	5.87	Wisconsin	5.40	0.17	(10)	9.16
Mississippi	4.55	0.23	(42)	-8.07	Wyoming	5.32	0.60	(12)	7.56
Missouri	5.26	0.17	(14)	6.33					



^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b Difference between state rate and total U.S. rate is statistically significant (p<=.0002).

^c Absolute percent difference between state rate and total U.S. rate is 15% or more.

SE Standard error of the rate.

PD Percent difference between state rate and total U.S. rate.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 19.25
Non-Hodgkin LymphomaEstimated United States Cancer Prevalence Counts^a on January 1, 2011
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <19 ^e	0 to <36 ^e	>=36 ^g	Complete ^h	
Race	Sex											
All Races ^b	Both Sexes	203,992	138,548	82,649	46,499	26,613	14,965	478,424	522,113	8,806	530,919	
	Males	109,031	71,416	42,880	24,393	14,018	8,043	251,155	274,206	4,630	278,836	
	Females	94,961	67,132	39,769	22,106	12,595	6,922	227,269	247,907	4,176	252,083	
White ^b	Both Sexes	176,587	121,718	73,137	41,335	23,890	13,662	418,719	458,521	9,171	467,692	
	Males	94,865	62,935	38,025	21,688	12,655	7,313	220,566	241,606	5,180	246,786	
	Females	81,722	58,783	35,112	19,647	11,235	6,349	198,153	216,915	3,991	220,906	
Black ^b	Both Sexes	16,393	11,194	5,958	3,101	1,826	801	37,209	39,725	715	40,440	
	Males	8,305	5,551	3,045	1,601	926	456	18,751	20,065	299	20,364	
	Females	8,088	5,643	2,913	1,500	900	345	18,458	19,660	416	20,076	
Asian/ Pacific Islander ^c	Both Sexes	5,757	3,689	2,092	+	+	+	12,532	+	+	+	
	Males	3,044	1,904	1,117	+	+	+	6,533	+	+	+	
	Females	2,713	1,785	975	+	+	+	5,999	+	+	+	
Hispanic ^d	Both Sexes	15,678	8,999	5,398	+	+	+	32,329	+	+	+	
	Males	8,083	4,633	2,885	+	+	+	16,751	+	+	+	
	Females	7,595	4,366	2,513	+	+	+	15,578	+	+	+	

Estimated prevalence percent^a on January 1, 2011, of the SEER^c population diagnosed in the previous 19 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence	All Ages	Age Specific (Crude)								Age-Adjusted ^f		
		0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages	
Race	Sex											
All Races ^c	Both Sexes	0.1349%	0.0032%	0.0117%	0.0244%	0.0455%	0.0974%	0.1924%	0.3624%	0.5763%	0.6536%	0.1311%
	Males	0.1439%	0.0039%	0.0156%	0.0294%	0.0537%	0.1144%	0.2225%	0.4110%	0.6473%	0.7399%	0.1504%
	Females	0.1260%	0.0025%	0.0077%	0.0191%	0.0373%	0.0806%	0.1637%	0.3184%	0.5192%	0.6031%	0.1143%
White ^c	Both Sexes	0.1516%	0.0033%	0.0121%	0.0257%	0.0477%	0.1031%	0.2075%	0.3920%	0.6328%	0.6985%	0.1412%
	Males	0.1608%	0.0042%	0.0164%	0.0311%	0.0564%	0.1210%	0.2388%	0.4395%	0.7091%	0.7841%	0.1612%
	Females	0.1423%	0.0024%	0.0076%	0.0200%	0.0385%	0.0847%	0.1766%	0.3477%	0.5699%	0.6479%	0.1232%
Black ^c	Both Sexes	0.0835%	0.0024%	0.0121%	0.0239%	0.0472%	0.0935%	0.1607%	0.2708%	0.3385%	0.3185%	0.0953%
	Males	0.0896%	0.0024%	0.0154%	0.0302%	0.0554%	0.1105%	0.1894%	0.3229%	0.3191%	0.3524%	0.1073%
	Females	0.0779%	0.0025%	0.0086%	0.0180%	0.0401%	0.0785%	0.1358%	0.2297%	0.3520%	0.3023%	0.0852%
Asian/ Pacific Islander ^c	Both Sexes	0.0828%	0.0036%	0.0090%	0.0174%	0.0299%	0.0604%	0.1147%	0.2145%	0.3575%	0.4777%	0.0835%
	Males	0.0895%	0.0039%	0.0115%	0.0199%	0.0347%	0.0680%	0.1318%	0.2465%	0.4247%	0.5732%	0.0977%
	Females	0.0768%	0.0032%	0.0064%	0.0148%	0.0257%	0.0537%	0.1001%	0.1880%	0.3059%	0.4190%	0.0724%
Hispanic ^d	Both Sexes	0.0646%	0.0032%	0.0089%	0.0184%	0.0328%	0.0729%	0.1482%	0.2770%	0.4412%	0.5261%	0.1014%
	Males	0.0657%	0.0040%	0.0115%	0.0216%	0.0390%	0.0810%	0.1665%	0.2893%	0.4502%	0.5719%	0.1098%
	Females	0.0635%	0.0025%	0.0061%	0.0148%	0.0262%	0.0645%	0.1307%	0.2664%	0.4345%	0.4989%	0.0939%

^a US 2011 cancer prevalence counts are based on 2011 cancer prevalence proportions from the SEER registries and 1/1/2011 US population estimates based on the average of 2010 and 2011 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^{b c d} Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia.

^e Maximum limited-duration prevalence: 36 years for 1975-2011 SEER 9 data; 19 years for 1992-2011 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

^f Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^{g h i} (g) Cases diagnosed more than 36 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <36 and >=36. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 19.26
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a
SEER^b Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Both Sexes, 2002-2011

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
Lymphoid Neoplasm	35.5	291,708	-0.1	5.8	13,801	0.9	23.5	124,330	-0.5*	158.8	153,577	0.0
1 Hodgkin Lymphoma	2.8	23,039	-0.4	1.2	2,871	1.1	3.2	16,085	-0.7	4.2	4,083	-0.1
2 Non-Hodgkin lymphoma	31.7	259,916	0.0	4.6	10,841	0.8	19.7	105,264	-0.3*	148.8	143,811	0.2
2(a) Non-Hodgkin lymphoma, B-cell	29.1	238,256	0.3	3.4	8,059	2.8*	17.8	94,938	-0.2	139.9	135,259	0.4
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	1.3	10,680	3.7*	2.8	6,477	3.4*	0.6	3,175	3.5*	1.1	1,028	5.6*
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	26.4	216,653	-0.1	0.6	1,483	-0.2	16.4	88,107	-0.4*	131.5	127,063	0.1
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	6.5	53,393	-1.1*	0.0	25	-	3.3	17,926	-1.3*	36.6	35,442	-0.9*
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	5.8	46,977	-1.4*	0.0	21	-	2.8	15,546	-1.7*	32.4	31,410	-1.3*
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	0.0	200	-2.3	-	-	-	0.0	51	-	0.2	145	-2.5
2(a) 2.1.3. Mantle-cell lymphoma	0.8	6,216	1.7*	0.0	0	-	0.4	2,329	0.9	4.0	3,887	2.1*
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	0.6	5,089	-1.7*	-	-	-	0.3	1,547	-2.2*	3.7	3,539	-1.5*
2(a) 2.2.1. Lymphoplasmacytic lymphoma	0.3	2,268	0.7	-	-	-	0.1	706	-0.6	1.6	1,561	1.2
2(a) 2.2.2. Waldenstrom macroglobulinemia	0.3	2,821	-3.5*	-	-	-	0.2	841	-3.5*	2.0	1,978	-3.5*
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	6.9	56,521	0.2	0.3	634	-1.5	4.6	24,273	-0.5	32.7	31,614	0.6*
2(a) 2.3.1. DLBCL, NOS ^c	6.9	55,999	0.1	0.3	612	-2.0	4.5	23,860	-0.7*	32.6	31,527	0.6*
2(a) 2.3.2. Intravascular large B-cell lymphoma	0.0	67	-	0.0	0	-	0.0	25	-	0.0	42	-
2(a) 2.3.3. Primary effusion lymphoma	0.0	92	-	0.0	0	-	0.0	71	-	0.0	21	-
2(a) 2.3.4. Mediastinal large B-cell lymphoma	0.0	363	10.9*	0.0	22	-	0.1	317	11.3*	0.0	24	-
2(a) 2.4. Burkitt lymphoma/leukemia	0.4	3,345	0.9	0.3	666	-0.5	0.4	1,940	2.7	0.8	739	-2.0
2(a) 2.5. Marginal-zone lymphoma (MZL)	1.9	15,680	1.7*	0.0	78	-	1.2	6,620	0.8*	9.3	8,982	2.2*
2(a) 2.5.1. Splenic MZL	0.2	1,317	0.1	0.0	0	-	0.1	523	-1.4	0.8	794	0.9
2(a) 2.5.2. Extranodal MZL, MALT ^c type	1.1	9,392	1.4*	0.0	51	-	0.8	4,225	0.6	5.3	5,116	1.9*
2(a) 2.5.3. Nodal MZL	0.6	4,971	2.7*	0.0	27	-	0.3	1,872	1.9*	3.2	3,072	3.0
2(a) 2.6. Follicular lymphoma	3.7	30,549	-0.8	0.0	67	-	3.0	15,697	-1.6*	15.3	14,785	-0.2
2(a) 2.7. Hairy-cell leukemia	0.3	2,456	-1.2	-	-	-	0.3	1,557	-0.9	0.9	898	-1.7
2(a) 2.8. Plasma cell neoplasms	6.1	49,576	0.7*	-	-	-	3.4	18,530	0.9*	32.2	31,037	0.6*
2(a) 2.8.1. Plasmacytoma	0.4	3,169	2.7*	-	-	-	0.3	1,564	2.4*	1.7	1,598	2.8*
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	5.7	46,407	0.6*	-	-	-	3.1	16,966	0.8*	30.5	29,439	0.5
2(a) 2.9. Heavy chain disease	0.0	44	-	0.0	0	-	0.0	17	-	0.0	27	-
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	1.3	10,923	5.1*	0.0	99	-	0.7	3,656	3.2*	7.4	7,168	5.9*

The APC is the Annual Percent Change over the time interval.

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.26 - continued
 All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes
 SEER^b Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Both Sexes, 2002-2011

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
2(b) Non-Hodgkin lymphoma, T-cell	2.1	17,302	0.3	0.8	1,776	0.8	1.7	8,954	0.2	6.8	6,572	0.2
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	0.2	1,292	-4.2	0.3	628	-3.2	0.1	559	-6.1	0.1	105	-
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	1.9	15,876	0.8	0.5	1,143	3.0*	1.6	8,327	0.8	6.6	6,406	0.4
2(b) 2.1. Mycosis fungoides/Sezary syndrome	0.5	3,953	1.0	0.0	91	-	0.5	2,370	1.1	1.5	1,492	0.6
2(b) 2.1.1. Mycosis fungoides	0.5	3,836	0.8	0.0	91	-	0.4	2,329	1.0	1.5	1,416	0.3
2(b) 2.1.2. Sezary syndrome	0.0	117	-	0.0	0	-	0.0	41	-	0.1	76	-
2(b) 2.2. Peripheral T-cell lymphoma	1.1	9,446	-0.2	0.2	412	-3.5	0.9	4,787	-0.3	4.4	4,247	0.1
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	0.4	3,358	0.1	0.0	74	-	0.3	1,599	-0.7	1.8	1,685	0.9
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	0.1	1,117	4.9*	-	-	-	0.1	448	3.9	0.7	666	5.3*
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	0.0	116	-	0.0	18	-	0.0	70	-	0.0	28	-
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	0.2	1,982	-3.5*	0.1	244	-4.2	0.2	1,125	-1.9	0.6	613	-5.7*
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	0.0	73	-	-	-	-	0.0	52	-	-	-	-
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	0.0	102	-	0.0	0	-	0.0	52	-	0.1	50	-
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	0.2	1,840	-1.0	0.0	30	-	0.2	978	-0.3	0.9	832	-2.0
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	0.1	858	0.4	0.0	31	-	0.1	463	0.4	0.4	364	0.7
2(b) 2.3. Adult T-cell leukemia/lymphoma	0.2	1,357	6.6*	0.3	613	7.3*	0.1	535	8.9*	0.2	209	0.0
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	0.1	644	3.5*	0.0	26	-	0.1	432	2.3	0.2	186	6.5*
2(b) 2.5. T-cell large granular lymphocytic leukemia	0.0	201	-	-	-	-	0.0	83	-	0.1	117	-
2(b) 2.6. Prolymphocytic leukemia, T-cell	0.0	275	3.2	0.0	0	-	0.0	120	-	0.2	155	4.0*
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	0.0	134	-	-	-	-	0.0	68	-	0.1	61	-
2(c) Non-Hodgkin lymphoma, unknown lineage	0.5	4,358	-12.2*	0.4	1,006	-13.8*	0.3	1,372	-11.6*	2.0	1,980	-11.3*
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	0.2	1,842	-12.8*	0.4	986	-13.8*	0.1	485	-11.9*	0.4	371	-10.1*
2(c) 2. Prolymphocytic leukemia, unknown lineage	0.0	100	-	-	-	-	0.0	31	-	0.1	67	-
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	0.3	2,416	-	0.0	18	-	0.2	856	-	1.6	1,542	-
2(*) 1. Total precursor lymphoma/leukemia ^d	1.7	13,814	0.5	3.4	8,091	0.6	0.8	4,219	0.2	1.6	1,504	1.1
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	0.0	157	5.8	-	-	-	0.0	85	-	0.1	70	-
4 Lymphoid neoplasm, NOS ^c	1.1	8,596	-4.3*	0.0	87	-	0.6	2,896	-5.1*	5.7	5,613	-4.1*

The APC is the Annual Percent Change over the time interval.

^a Morton LM, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.27
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a
SEER^b Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Males, 2002-2011

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
Lymphoid Neoplasm	43.9	161,493	-0.2	6.7	8,048	0.6	28.0	72,662	-0.6*	201.9	80,783	0.1
1 Hodgkin Lymphoma	3.1	12,578	-0.3	1.3	1,539	1.3	3.5	8,879	-0.6	5.3	2,160	-0.2
2 Non-Hodgkin lymphoma	39.5	144,319	0.0	5.4	6,456	0.4	23.8	61,995	-0.5*	189.5	75,868	0.2
2(a) Non-Hodgkin lymphoma, B-cell	36.1	131,660	0.3	3.8	4,643	2.4*	21.4	55,804	-0.3	177.9	71,213	0.5*
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	1.4	5,812	3.3*	3.0	3,556	2.8*	0.7	1,768	3.2*	1.2	488	7.0*
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	33.1	120,149	-0.1	0.8	1,019	0.4	19.9	51,935	-0.6*	167.8	67,195	0.2
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	9.1	32,375	-1.1*	-	-	-	4.4	11,734	-1.5*	51.6	20,628	-1.0
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	7.9	27,904	-1.5*	-	-	-	3.7	9,975	-1.9*	44.9	17,917	-1.4*
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	0.0	125	-	-	-	-	0.0	33	-	0.2	91	-
2(a) 2.1.3. Mantle-cell lymphoma	1.2	4,346	1.4	0.0	0	-	0.6	1,726	0.8	6.5	2,620	1.8
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	0.8	2,943	-2.5*	-	-	-	0.3	897	-2.3*	5.2	2,045	-2.6*
2(a) 2.2.1. Lymphoplasmacytic lymphoma	0.4	1,244	-0.5	0.0	0	-	0.1	389	-2.0	2.2	855	0.0
2(a) 2.2.2. Waldenstrom macroglobulinemia	0.5	1,699	-4.0*	-	-	-	0.2	508	-2.7	3.0	1,190	-4.4*
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	8.4	30,688	0.5*	0.3	367	-1.4	5.7	14,584	-0.4	39.5	15,737	1.2*
2(a) 2.3.1. DLBCL, NOS ^c	8.3	30,427	0.5	0.3	360	-1.9	5.6	14,376	-0.5	39.4	15,691	1.2*
2(a) 2.3.2. Intravascular large B-cell lymphoma	0.0	32	-	0.0	0	-	-	-	-	0.0	18	-
2(a) 2.3.3. Primary effusion lymphoma	0.0	83	-	0.0	0	-	0.0	67	-	0.0	16	-
2(a) 2.3.4. Mediastinal large B-cell lymphoma	0.0	146	-	-	-	-	0.1	127	-	-	-	-
2(a) 2.4. Burkitt lymphoma/leukemia	0.6	2,434	0.6	0.4	527	-0.1	0.6	1,485	2.1	1.0	422	-2.7
2(a) 2.5. Marginal-zone lymphoma (MZL)	2.0	7,291	2.1*	0.0	53	-	1.2	3,184	1.0*	10.1	4,054	2.6*
2(a) 2.5.1. Splenic MZL	0.2	630	-0.6	0.0	0	-	0.1	261	-3.0	0.9	369	0.6
2(a) 2.5.2. Extranodal MZL, MALT ^c type	1.2	4,253	1.8*	0.0	32	-	0.8	1,955	1.1	5.6	2,266	2.0*
2(a) 2.5.3. Nodal MZL	0.7	2,408	3.5*	0.0	21	-	0.4	968	1.9	3.6	1,419	4.3*
2(a) 2.6. Follicular lymphoma	4.0	15,123	-0.9	0.0	52	-	3.2	8,201	-2.0*	16.9	6,870	0.0
2(a) 2.7. Hairy-cell leukemia	0.5	1,944	-0.8	-	-	-	0.5	1,261	-0.5	1.7	682	-1.2
2(a) 2.8. Plasma cell neoplasms	7.6	27,320	0.7*	-	-	-	4.0	10,578	0.7*	41.7	16,737	0.7
2(a) 2.8.1. Plasmacytoma	0.5	1,982	2.1*	-	-	-	0.4	1,022	1.6	2.4	956	2.4*
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	7.1	25,338	0.6*	-	-	-	3.6	9,556	0.6	39.4	15,781	0.6
2(a) 2.9. Heavy chain disease	0.0	31	-	0.0	0	-	-	-	-	0.1	20	-
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	1.6	5,699	5.2*	0.1	68	-	0.8	2,101	3.6	9.0	3,530	5.8*

The APC is the Annual Percent Change over the time interval.

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.27 - continued
 All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes
 SEER^b Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Males, 2002-2011

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
2(b) Non-Hodgkin lymphoma, T-cell	2.7	10,294	0.1	1.0	1,234	0.8	2.1	5,340	0.3	9.2	3,720	-0.4
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	0.2	884	-3.7	0.4	450	-3.2	0.2	379	-4.9	0.1	55	-
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	2.5	9,335	0.6	0.6	780	3.2*	1.9	4,924	1.0	9.0	3,631	-0.3
2(b) 2.1. Mycosis fungoides/Sezary syndrome	0.6	2,247	0.6	0.0	40	-	0.5	1,303	2.4	2.2	904	-1.2
2(b) 2.1.1. Mycosis fungoides	0.6	2,180	0.4	0.0	40	-	0.5	1,281	2.2	2.1	859	-1.6
2(b) 2.1.2. Sezary syndrome	0.0	67	-	0.0	0	-	0.0	22	-	0.1	45	-
2(b) 2.2. Peripheral T-cell lymphoma	1.5	5,513	-0.5	0.2	259	-4.9	1.1	2,885	-0.5	5.9	2,369	-0.1
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	0.5	2,002	0.7	0.0	49	-	0.4	1,017	-0.3	2.3	936	1.9
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	0.2	577	3.8*	-	-	-	0.1	246	4.2	0.8	329	3.5
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	0.0	37	-	-	-	-	0.0	20	-	-	-	-
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	0.3	1,224	-4.5*	0.1	160	-	0.3	707	-3.4	0.9	357	-5.3*
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	0.0	49	-	-	-	-	0.0	32	-	-	-	-
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	0.0	57	-	0.0	0	-	0.0	28	-	0.1	29	-
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	0.3	1,060	-1.0	-	-	-	0.2	578	-0.6	1.1	467	-1.6
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	0.1	507	-0.2	0.0	17	-	0.1	257	1.7	0.6	233	-1.8
2(b) 2.3. Adult T-cell leukemia/lymphoma	0.2	913	7.1*	0.4	460	7.9*	0.1	348	9.2*	0.3	105	-
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	0.1	414	3.5	0.0	21	-	0.1	285	2.4	0.3	108	-
2(b) 2.5. T-cell large granular lymphocytic leukemia	0.0	95	-	0.0	0	-	0.0	31	-	0.2	64	-
2(b) 2.6. Prolymphocytic leukemia, T-cell	0.0	153	2.0	0.0	0	-	0.0	72	-	0.2	81	-
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	0.0	75	-	-	-	-	0.0	37	-	0.1	34	-
2(c) Non-Hodgkin lymphoma, unknown lineage	0.6	2,365	-13.2*	0.5	579	-15.1*	0.3	851	-	2.4	935	-12.3*
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	0.3	1,028	-13.8*	0.5	566	-15.1*	0.1	281	-	0.5	181	-10.4*
2(c) 2. Prolymphocytic leukemia, unknown lineage	0.0	60	-	-	-	-	0.0	18	-	0.1	41	-
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	0.4	1,277	-	-	-	-	0.2	552	-	1.8	713	-
2(*) 1. Total precursor lymphoma/leukemia ^d	1.9	7,724	0.0	3.8	4,572	-0.2	1.0	2,428	-0.4	1.8	724	1.7
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	0.0	81	-	-	-	-	0.0	48	-	0.1	32	-
4 Lymphoid neoplasm, NOS ^c	1.3	4,515	-4.4*	0.0	52	-	0.7	1,740	-5.8*	7.0	2,723	-3.8*

The APC is the Annual Percent Change over the time interval.

^a Morton LM, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.28
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a
SEER^b Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Females, 2002-2011

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
Lymphoid Neoplasm	29.0	130,215	-0.2	5.0	5,753	1.4*	19.2	51,668	-0.3	128.7	72,794	-0.3
1 Hodgkin Lymphoma	2.5	10,461	-0.5	1.1	1,332	0.8	2.9	7,206	-0.9	3.5	1,923	-0.1
2 Non-Hodgkin lymphoma	25.6	115,597	0.0	3.8	4,385	1.4*	15.9	43,269	-0.1	120.3	67,943	-0.1
2(a) Non-Hodgkin lymphoma, B-cell	23.6	106,596	0.2	3.0	3,416	3.4*	14.3	39,134	0.0	113.4	64,046	0.1
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	1.2	4,868	4.2*	2.5	2,921	4.2*	0.5	1,407	4.0*	1.0	540	4.3*
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	21.3	96,504	-0.2	0.4	464	-1.8	13.2	36,172	-0.2	106.1	59,868	-0.2
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	4.6	21,018	-1.2*	-	-	-	2.2	6,192	-1.0	26.0	14,814	-1.2*
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	4.1	19,073	-1.5*	-	-	-	2.0	5,571	-1.2*	23.6	13,493	-1.6*
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	0.0	75	-	-	-	-	0.0	18	-	0.1	54	-
2(a) 2.1.3. Mantle-cell lymphoma	0.4	1,870	2.0	0.0	0	-	0.2	603	1.3	2.3	1,267	2.2
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	0.5	2,146	-0.9*	-	-	-	0.2	650	-2.0	2.6	1,494	-0.5
2(a) 2.2.1. Lymphoplasmacytic lymphoma	0.2	1,024	1.7*	-	-	-	0.1	317	1.1	1.3	706	2.0*
2(a) 2.2.2. Waldenstrom macroglobulinemia	0.2	1,122	-3.4*	-	-	-	0.1	333	-4.8*	1.4	788	-2.8*
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	5.7	25,833	-0.3	0.2	267	-2.0	3.6	9,689	-0.6	28.0	15,877	-0.1
2(a) 2.3.1. DLBCL, NOS ^c	5.7	25,572	-0.4	0.2	252	-2.3	3.5	9,484	-0.8*	28.0	15,836	-0.1
2(a) 2.3.2. Intravascular large B-cell lymphoma	0.0	35	-	0.0	0	-	-	-	-	0.0	24	-
2(a) 2.3.3. Primary effusion lymphoma	-	-	-	0.0	0	-	-	-	-	-	-	-
2(a) 2.3.4. Mediastinal large B-cell lymphoma	0.1	217	-	-	-	-	0.1	190	-	-	-	-
2(a) 2.4. Burkitt lymphoma/leukemia	0.2	911	1.3	0.1	139	-	0.2	455	4.5*	0.6	317	-1.3
2(a) 2.5. Marginal-zone lymphoma (MZL)	1.9	8,389	1.2*	0.0	25	-	1.3	3,436	0.6	8.8	4,928	1.6
2(a) 2.5.1. Splenic MZL	0.2	687	0.6	0.0	0	-	0.1	262	0.2	0.8	425	0.8
2(a) 2.5.2. Extranodal MZL, MALT ^c type	1.1	5,139	0.9	0.0	19	-	0.8	2,270	0.1	5.1	2,850	1.6
2(a) 2.5.3. Nodal MZL	0.6	2,563	1.9	-	-	-	0.3	904	2.0	2.9	1,653	1.8
2(a) 2.6. Follicular lymphoma	3.4	15,426	-0.8	-	-	-	2.8	7,496	-1.1	14.3	7,915	-0.4
2(a) 2.7. Hairy-cell leukemia	0.1	512	-3.1*	0.0	0	-	0.1	296	-2.1	0.4	216	-4.1
2(a) 2.8. Plasma cell neoplasms	4.9	22,256	0.6	-	-	-	2.8	7,952	1.3	25.4	14,300	0.2
2(a) 2.8.1. Plasmacytoma	0.3	1,187	3.6*	-	-	-	0.2	542	4.1*	1.1	642	3.0
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	4.6	21,069	0.4	-	-	-	2.7	7,410	1.1	24.3	13,658	0.0
2(a) 2.9. Heavy chain disease	-	-	-	0.0	0	-	-	-	-	-	-	-
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	1.1	5,224	4.7*	0.0	31	-	0.6	1,555	2.4	6.3	3,638	5.6*

The APC is the Annual Percent Change over the time interval.

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.28 - continued
 All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes
 SEER^b Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Females, 2002-2011

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
2(b) Non-Hodgkin lymphoma, T-cell	1.6	7,008	0.4	0.5	542	0.7	1.4	3,614	-0.1	5.1	2,852	0.8
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	0.1	408	-5.1*	0.2	178	-3.2	0.1	180	-8.2*	0.1	50	-
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	1.5	6,541	0.9*	0.3	363	2.6	1.3	3,403	0.5	5.0	2,775	1.0
2(b) 2.1. Mycosis fungoides/Sezary syndrome	0.4	1,706	1.1	0.0	51	-	0.4	1,067	-0.2	1.1	588	3.0
2(b) 2.1.1. Mycosis fungoides	0.4	1,656	1.0	0.0	51	-	0.4	1,048	-0.3	1.0	557	2.8
2(b) 2.1.2. Sezary syndrome	0.0	50	-	0.0	0	-	0.0	19	-	0.1	31	-
2(b) 2.2. Peripheral T-cell lymphoma	0.9	3,933	0.1	0.1	153	-	0.7	1,902	0.1	3.3	1,878	0.3
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	0.3	1,356	-0.8	0.0	25	-	0.2	582	-1.5	1.3	749	-0.3
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	0.1	540	5.7*	-	-	-	0.1	202	3.3	0.6	337	7.1*
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	0.0	79	-	-	-	-	0.0	50	-	0.0	16	-
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	0.2	758	-1.8	0.1	84	-	0.2	418	1.0	0.5	256	-6.5
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	0.0	24	-	-	-	-	0.0	20	-	-	-	-
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	0.0	45	-	0.0	0	-	0.0	24	-	0.0	21	-
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	0.2	780	-1.1	-	-	-	0.2	400	0.1	0.7	365	-2.7
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	0.1	351	0.7	-	-	-	0.1	206	-0.3	0.2	131	-
2(b) 2.3. Adult T-cell leukemia/lymphoma	0.1	444	5.6*	0.1	153	-	0.1	187	7.8	0.2	104	-
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	0.1	230	3.6	-	-	-	0.1	147	-	0.1	78	-
2(b) 2.5. T-cell large granular lymphocytic leukemia	0.0	106	-	-	-	-	0.0	52	-	0.1	53	-
2(b) 2.6. Prolymphocytic leukemia, T-cell	0.0	122	-	0.0	0	-	0.0	48	-	0.1	74	-
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	0.0	59	-	-	-	-	0.0	31	-	0.0	27	-
2(c) Non-Hodgkin lymphoma, unknown lineage	0.5	1,993	-11.2*	0.4	427	-11.9*	0.2	521	-10.5*	1.8	1,045	-10.5*
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	0.2	814	-11.2*	0.4	420	-11.9*	0.1	204	-9.5*	0.3	190	-10.3*
2(c) 2. Prolymphocytic leukemia, unknown lineage	0.0	40	-	-	-	-	-	-	-	0.0	26	-
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	0.3	1,139	-	-	-	-	0.1	304	-	1.4	829	-
2(*) 1. Total precursor lymphoma/leukemia ^d	1.5	6,090	1.4*	3.1	3,519	1.7*	0.7	1,791	1.1	1.4	780	0.5
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	0.0	76	-	-	-	-	0.0	37	-	0.1	38	-
4 Lymphoid neoplasm, NOS ^c	0.9	4,081	-4.2*	0.0	35	-	0.4	1,156	-4.0*	4.9	2,890	-4.5*

The APC is the Annual Percent Change over the time interval.

^a Morton LM, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.29
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2004-2010

Site	Count	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
		Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)		
Lymphoid Neoplasm	169,687	68.1 (67.8 , 68.4)	89.0 (88.3 , 89.7)	75.8 (75.4 , 76.1)	57.4 (56.9 , 57.9)				
1 Hodgkin Lymphoma	14,949	85.3 (84.6 , 86.0)	96.4 (95.3 , 97.3)	89.4 (88.7 , 90.1)	52.8 (49.9 , 55.6)				
2 Non-Hodgkin lymphoma	150,164	66.9 (66.6 , 67.3)	87.0 (86.1 , 87.8)	74.0 (73.5 , 74.4)	58.1 (57.6 , 58.7)				
2(a) Non-Hodgkin lymphoma, B-cell	137,405	67.4 (67.0 , 67.7)	88.0 (87.0 , 88.9)	74.9 (74.5 , 75.3)	58.8 (58.2 , 59.3)				
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	7,176	67.6 (66.3 , 68.8)	88.0 (86.8 , 89.0)	35.4 (33.0 , 37.8)	14.0 (10.5 , 17.9)				
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	124,162	67.3 (67.0 , 67.7)	88.2 (86.0 , 90.1)	76.3 (75.9 , 76.7)	59.0 (58.4 , 59.5)				
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	29,600	76.4 (75.6 , 77.1)	- (- , -)	85.3 (84.4 , 86.2)	70.4 (69.2 , 71.5)				
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	26,077	79.2 (78.4 , 80.0)	- (- , -)	88.1 (87.2 , 89.0)	73.4 (72.2 , 74.6)				
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	114	41.6 (29.9 , 52.9)	- (- , -)	51.2 (30.8 , 68.3)	36.1 (21.9 , 50.5)				
2(a) 2.1.3. Mantle-cell lymphoma	3,409	55.6 (53.2 , 57.8)	- (- , -)	67.5 (64.4 , 70.5)	46.0 (42.6 , 49.2)				
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	2,699	78.2 (75.5 , 80.7)	- (- , -)	85.1 (81.7 , 87.8)	74.1 (70.2 , 77.6)				
2(a) 2.2.1. Lymphoplasmacytic lymphoma	1,207	74.0 (69.7 , 77.8)	- (- , -)	80.7 (75.0 , 85.3)	70.1 (64.0 , 75.3)				
2(a) 2.2.2. Waldenstrom macroglobulinemia	1,492	81.5 (77.9 , 84.6)	- (- , -)	88.3 (84.0 , 91.5)	77.3 (71.9 , 81.7)				
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	32,750	60.5 (59.8 , 61.1)	86.4 (82.6 , 89.4)	69.9 (69.0 , 70.7)	50.7 (49.6 , 51.8)				
2(a) 2.3.1. DLBCL, NOS ^c	32,385	60.3 (59.6 , 61.0)	87.3 (83.5 , 90.2)	69.8 (68.9 , 70.6)	50.7 (49.6 , 51.8)				
2(a) 2.3.2. Intravascular large B-cell lymphoma	36	54.8 (34.6 , 71.2)	- (- , -)	- (- , -)	- (- , -)				
2(a) 2.3.3. Primary effusion lymphoma	54	22.5 (10.8 , 36.8)	- (- , -)	24.8 (11.6 , 40.5)	- (- , -)				
2(a) 2.3.4. Mediastinal large B-cell lymphoma	275	81.8 (75.3 , 86.8)	- (- , -)	86.4 (80.2 , 90.7)	- (- , -)				
2(a) 2.4. Burkitt lymphoma/leukemia	2,200	58.3 (56.0 , 60.6)	88.6 (85.2 , 91.3)	55.8 (52.8 , 58.6)	31.0 (25.1 , 37.1)				
2(a) 2.5. Marginal-zone lymphoma (MZL)	8,856	90.0 (88.8 , 91.2)	98.2 (87.7 , 99.7)	92.9 (91.6 , 93.9)	87.4 (85.1 , 89.3)				
2(a) 2.5.1. Splenic MZL	756	84.8 (80.1 , 88.4)	- (- , -)	87.7 (82.3 , 91.5)	81.8 (74.3 , 87.3)				
2(a) 2.5.2. Extranodal MZL, MALT ^c type	5,326	94.0 (92.4 , 95.3)	97.4 (82.7 , 99.6)	95.7 (94.2 , 96.8)	92.2 (89.0 , 94.5)				
2(a) 2.5.3. Nodal MZL	2,774	83.5 (81.1 , 85.6)	- (- , -)	87.8 (84.9 , 90.1)	79.9 (76.1 , 83.1)				
2(a) 2.6. Follicular lymphoma	18,039	86.1 (85.3 , 86.9)	91.8 (75.9 , 97.4)	90.6 (89.8 , 91.4)	79.9 (78.3 , 81.5)				
2(a) 2.7. Hairy-cell leukemia	1,470	93.6 (90.8 , 95.5)	- (- , -)	97.6 (95.8 , 98.7)	82.5 (74.7 , 88.1)				
2(a) 2.8. Plasma cell neoplasms	28,523	44.6 (43.8 , 45.4)	- (- , -)	57.4 (56.3 , 58.6)	34.8 (33.7 , 35.8)				
2(a) 2.8.1. Plasmacytoma	1,778	65.0 (61.8 , 67.9)	- (- , -)	77.4 (73.8 , 80.5)	48.7 (43.5 , 53.7)				
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	26,745	43.3 (42.4 , 44.1)	- (- , -)	55.7 (54.5 , 56.9)	34.0 (32.9 , 35.1)				
2(a) 2.9. Heavy chain disease	25	66.6 (34.1 , 85.7)	- (- , -)	- (- , -)	- (- , -)				
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	6,067	67.5 (65.7 , 69.2)	83.3 (65.2 , 92.5)	75.4 (73.2 , 77.5)	62.1 (59.4 , 64.6)				

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.29 - continued
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2004-2010

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
2(b) Non-Hodgkin lymphoma, T-cell	10,320	63.1 (61.9 , 64.2)	83.3 (81.0 , 85.5)	66.3 (64.9 , 67.7)	49.6 (47.1 , 52.0)			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	884	62.4 (58.7 , 65.8)	84.5 (80.5 , 87.8)	44.8 (39.3 , 50.2)	8.0 (2.1 , 19.0)			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	9,351	63.4 (62.2 , 64.6)	82.7 (79.6 , 85.4)	68.1 (66.6 , 69.5)	50.7 (48.2 , 53.2)			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	2,319	89.4 (87.1 , 91.4)	94.9 (77.3 , 98.9)	93.0 (90.9 , 94.7)	80.7 (74.3 , 85.6)			
2(b) 2.1.1. Mycosis fungoides	2,254	90.6 (88.3 , 92.5)	94.9 (77.3 , 98.9)	93.6 (91.5 , 95.2)	83.0 (76.4 , 87.9)			
2(b) 2.1.2. Sezary syndrome	65	44.1 (26.8 , 60.2)	- (- , -)	57.1 (30.1 , 77.0)	33.3 (12.4 , 56.0)			
2(b) 2.2. Peripheral T-cell lymphoma	5,466	56.0 (54.4 , 57.6)	81.6 (76.2 , 85.9)	62.4 (60.4 , 64.4)	43.2 (40.3 , 46.1)			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	1,836	37.0 (34.3 , 39.7)	60.4 (44.1 , 73.4)	42.5 (38.8 , 46.1)	29.1 (25.0 , 33.4)			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	700	43.4 (38.7 , 47.9)	- (- , -)	52.6 (46.1 , 58.7)	35.2 (28.8 , 41.7)			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	76	61.6 (44.0 , 75.2)	- (- , -)	64.0 (41.2 , 79.9)	- (- , -)			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	1,189	58.1 (54.9 , 61.2)	85.2 (78.7 , 89.9)	62.0 (58.1 , 65.7)	32.0 (25.5 , 38.8)			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	43	26.8 (13.9 , 41.5)	- (- , -)	26.8 (12.0 , 44.2)	- (- , -)			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	65	13.3 (5.4 , 25.0)	- (- , -)	16.5 (5.3 , 33.1)	11.9 (3.0 , 27.5)			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	1,055	81.1 (77.2 , 84.4)	- (- , -)	85.8 (81.7 , 89.1)	73.0 (65.0 , 79.4)			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	502	90.9 (86.3 , 94.0)	- (- , -)	94.5 (89.1 , 97.2)	81.3 (69.2 , 89.0)			
2(b) 2.3. Adult T-cell leukemia/lymphoma	866	57.0 (53.2 , 60.7)	82.7 (78.3 , 86.3)	36.7 (30.5 , 42.8)	19.8 (11.4 , 29.8)			
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	412	41.6 (35.9 , 47.2)	- (- , -)	39.8 (33.3 , 46.2)	43.5 (31.1 , 55.2)			
2(b) 2.5. T-cell large granular lymphocytic leukemia	140	64.4 (52.3 , 74.2)	- (- , -)	75.8 (59.1 , 86.4)	54.7 (37.7 , 68.9)			
2(b) 2.6. Prolymphocytic leukemia, T-cell	148	21.5 (13.4 , 30.9)	- (- , -)	29.8 (18.7 , 41.7)	14.8 (5.8 , 27.8)			
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	85	36.5 (25.1 , 48.1)	- (- , -)	52.5 (35.9 , 66.7)	12.2 (2.7 , 29.4)			
2(c) Non-Hodgkin lymphoma, unknown lineage	2,439	59.0 (56.6 , 61.3)	85.5 (82.4 , 88.0)	56.1 (52.2 , 59.8)	42.0 (37.7 , 46.1)			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	1,075	64.7 (61.6 , 67.6)	85.8 (82.7 , 88.4)	37.7 (31.3 , 44.1)	19.3 (12.4 , 27.4)			
2(c) 2. Prolymphocytic leukemia, unknown lineage	57	48.5 (33.5 , 62.0)	- (- , -)	- (- , -)	38.8 (20.6 , 56.7)			
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	1,307	54.2 (50.7 , 57.6)	- (- , -)	64.9 (60.0 , 69.3)	46.4 (41.5 , 51.2)			
2(*) 1. Total precursor lymphoma/leukemia ^d	9,135	66.8 (65.7 , 67.9)	87.5 (86.4 , 88.4)	37.1 (35.0 , 39.2)	14.6 (11.6 , 18.0)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	83	60.1 (45.8 , 71.7)	- (- , -)	63.5 (46.1 , 76.6)	53.4 (29.0 , 72.7)			
4 Lymphoid neoplasm, NOS ^c	4,491	48.8 (46.9 , 50.7)	84.5 (72.3 , 91.6)	61.4 (58.6 , 64.0)	39.8 (37.2 , 42.4)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.

Table 19.30
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2004-2010

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
Lymphoid Neoplasm	93,448	67.7 (67.3 , 68.1)	88.3 (87.3 , 89.2)	73.8 (73.3 , 74.3)	57.1 (56.3 , 57.9)			
1 Hodgkin Lymphoma	8,123	84.4 (83.4 , 85.3)	96.8 (95.3 , 97.8)	87.7 (86.6 , 88.6)	52.6 (48.2 , 56.8)			
2 Non-Hodgkin lymphoma	82,956	66.5 (66.1 , 67.0)	86.3 (85.1 , 87.4)	72.1 (71.6 , 72.7)	57.8 (57.0 , 58.5)			
2(a) Non-Hodgkin lymphoma, B-cell	75,497	67.0 (66.6 , 67.5)	87.6 (86.2 , 88.9)	73.2 (72.6 , 73.8)	58.4 (57.6 , 59.2)			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	3,960	67.9 (66.2 , 69.6)	87.2 (85.6 , 88.7)	35.3 (32.2 , 38.5)	17.1 (11.4 , 23.6)			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	68,370	67.0 (66.5 , 67.5)	89.5 (86.8 , 91.7)	74.5 (73.9 , 75.1)	58.6 (57.7 , 59.4)			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	17,804	75.0 (73.9 , 76.0)	- (- , -)	83.5 (82.3 , 84.7)	68.3 (66.7 , 69.8)			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	15,341	78.2 (77.1 , 79.3)	- (- , -)	86.5 (85.3 , 87.7)	71.8 (70.1 , 73.5)			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	69	51.0 (34.3 , 65.4)	- (- , -)	- (- , -)	48.4 (29.1 , 65.2)			
2(a) 2.1.3. Mantle-cell lymphoma	2,394	54.9 (52.1 , 57.7)	- (- , -)	66.7 (63.0 , 70.2)	44.0 (39.9 , 48.0)			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	1,547	79.4 (75.8 , 82.6)	- (- , -)	84.3 (79.9 , 87.9)	76.3 (71.0 , 80.7)			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	660	75.8 (69.9 , 80.7)	- (- , -)	79.8 (72.3 , 85.6)	73.0 (64.3 , 79.9)			
2(a) 2.2.2. Waldenstrom macroglobulinemia	887	81.9 (77.4 , 85.6)	- (- , -)	87.5 (81.6 , 91.7)	77.7 (71.2 , 82.9)			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	17,715	60.4 (59.4 , 61.3)	89.0 (84.1 , 92.5)	67.3 (66.2 , 68.4)	50.8 (49.2 , 52.5)			
2(a) 2.3.1. DLBCL, NOS ^c	17,539	60.4 (59.4 , 61.3)	89.3 (84.3 , 92.8)	67.3 (66.2 , 68.4)	51.0 (49.3 , 52.6)			
2(a) 2.3.2. Intravascular large B-cell lymphoma	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(a) 2.3.3. Primary effusion lymphoma	49	22.0 (9.6 , 37.7)	- (- , -)	22.9 (9.7 , 39.4)	- (- , -)			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	109	78.2 (66.1 , 86.5)	- (- , -)	86.5 (74.9 , 93.0)	- (- , -)			
2(a) 2.4. Burkitt lymphoma/leukemia	1,611	58.9 (56.2 , 61.5)	88.8 (85.0 , 91.7)	54.9 (51.5 , 58.2)	25.2 (17.3 , 34.0)			
2(a) 2.5. Marginal-zone lymphoma (MZL)	4,068	89.4 (87.4 , 91.1)	100.0 (- , -)	91.1 (89.1 , 92.8)	87.1 (83.5 , 89.9)			
2(a) 2.5.1. Splenic MZL	353	86.6 (79.1 , 91.6)	- (- , -)	84.6 (75.8 , 90.4)	88.2 (73.9 , 94.9)			
2(a) 2.5.2. Extranodal MZL, MALT ^c type	2,389	93.1 (90.4 , 95.0)	- (- , -)	94.4 (91.9 , 96.1)	91.3 (85.6 , 94.9)			
2(a) 2.5.3. Nodal MZL	1,326	82.8 (79.1 , 85.8)	- (- , -)	86.0 (81.7 , 89.4)	79.2 (73.2 , 84.0)			
2(a) 2.6. Follicular lymphoma	8,950	85.5 (84.3 , 86.6)	92.5 (71.8 , 98.2)	89.2 (88.0 , 90.3)	79.4 (76.9 , 81.8)			
2(a) 2.7. Hairy-cell leukemia	1,176	94.2 (91.0 , 96.2)	- (- , -)	97.7 (95.5 , 98.8)	83.6 (74.1 , 89.9)			
2(a) 2.8. Plasma cell neoplasms	15,480	45.8 (44.7 , 46.9)	- (- , -)	57.1 (55.6 , 58.6)	35.9 (34.3 , 37.4)			
2(a) 2.8.1. Plasmacytoma	1,092	68.4 (64.5 , 72.0)	- (- , -)	78.5 (74.1 , 82.3)	52.3 (45.3 , 58.7)			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	14,388	44.0 (42.9 , 45.2)	- (- , -)	54.9 (53.3 , 56.5)	34.9 (33.3 , 36.4)			
2(a) 2.9. Heavy chain disease	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	3,167	66.8 (64.2 , 69.1)	76.3 (49.8 , 90.1)	73.1 (70.0 , 75.9)	61.5 (57.6 , 65.2)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.30 - continued
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2004-2010

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)		
2(b) Non-Hodgkin lymphoma, T-cell	6,159	62.1 (60.6 , 63.6)	82.7 (79.8 , 85.2)	63.5 (61.6 , 65.4)	48.8 (45.4 , 52.1)			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	615	62.6 (58.3 , 66.7)	83.0 (78.1 , 86.9)	43.5 (36.8 , 50.0)	- (- , -)			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	5,500	62.2 (60.5 , 63.8)	82.5 (78.8 , 85.7)	65.3 (63.3 , 67.2)	49.8 (46.3 , 53.2)			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	1,302	88.5 (85.2 , 91.2)	100.0 (- , -)	92.6 (89.6 , 94.7)	78.2 (69.3 , 84.8)			
2(b) 2.1.1. Mycosis fungoides	1,263	89.6 (86.2 , 92.2)	100.0 (- , -)	93.4 (90.4 , 95.4)	79.6 (70.3 , 86.3)			
2(b) 2.1.2. Sezary syndrome	39	50.7 (30.3 , 68.0)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2. Peripheral T-cell lymphoma	3,194	54.4 (52.2 , 56.5)	78.5 (71.2 , 84.2)	59.1 (56.4 , 61.7)	42.7 (38.8 , 46.6)			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	1,093	36.2 (32.6 , 39.8)	56.4 (35.9 , 72.6)	39.5 (34.8 , 44.0)	29.9 (23.9 , 36.1)			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	361	37.9 (31.6 , 44.3)	- (- , -)	48.8 (39.7 , 57.3)	27.0 (18.8 , 36.0)			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	28	61.2 (18.3 , 86.7)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	748	56.1 (52.0 , 59.9)	84.5 (75.8 , 90.2)	57.3 (52.3 , 62.0)	31.8 (23.2 , 40.7)			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	29	24.2 (10.1 , 41.6)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	37	0.0 (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	618	80.4 (75.3 , 84.6)	- (- , -)	84.6 (78.7 , 88.9)	72.6 (61.8 , 80.8)			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	280	89.8 (82.9 , 94.0)	- (- , -)	94.0 (87.7 , 97.1)	80.6 (64.0 , 90.2)			
2(b) 2.3. Adult T-cell leukemia/lymphoma	597	61.5 (56.8 , 65.8)	83.9 (79.0 , 87.7)	38.8 (31.0 , 46.4)	9.6 (1.7 , 26.2)			
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	269	41.5 (34.5 , 48.3)	- (- , -)	39.2 (31.3 , 46.9)	39.0 (24.6 , 53.2)			
2(b) 2.5. T-cell large granular lymphocytic leukemia	65	52.2 (35.1 , 66.8)	- (- , -)	72.5 (47.3 , 87.1)	38.1 (18.3 , 57.8)			
2(b) 2.6. Prolymphocytic leukemia, T-cell	73	21.6 (11.4 , 34.0)	- (- , -)	31.3 (16.1 , 47.8)	10.0 (1.8 , 26.8)			
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	44	44.9 (27.5 , 60.9)	- (- , -)	- (- , -)	- (- , -)			
2(c) Non-Hodgkin lymphoma, unknown lineage	1,300	58.3 (55.1 , 61.3)	83.4 (79.0 , 87.0)	53.1 (48.2 , 57.8)	40.5 (34.3 , 46.7)			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	596	63.7 (59.5 , 67.7)	83.8 (79.4 , 87.4)	33.7 (25.8 , 41.7)	23.4 (13.0 , 35.6)			
2(c) 2. Prolymphocytic leukemia, unknown lineage	32	38.2 (20.4 , 56.0)	- (- , -)	- (- , -)	- (- , -)			
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	672	53.9 (49.1 , 58.5)	- (- , -)	62.6 (56.5 , 68.1)	44.4 (37.0 , 51.5)			
2(*) 1. Total precursor lymphoma/leukemia ^d	5,171	66.9 (65.4 , 68.3)	86.4 (85.0 , 87.7)	36.7 (34.0 , 39.4)	17.5 (12.7 , 22.9)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	45	69.6 (49.6 , 82.9)	- (- , -)	65.6 (44.7 , 80.2)	- (- , -)			
4 Lymphoid neoplasm, NOS ^c	2,324	49.4 (46.7 , 52.0)	82.9 (65.8 , 91.9)	59.0 (55.4 , 62.3)	39.7 (35.8 , 43.5)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.

Table 19.31
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2004-2010

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
Lymphoid Neoplasm	76,239	68.6 (68.2 , 69.1)	90.0 (88.9 , 91.0)	78.6 (78.1 , 79.1)	57.7 (56.9 , 58.4)			
1 Hodgkin Lymphoma	6,826	86.4 (85.4 , 87.3)	96.0 (94.2 , 97.2)	91.5 (90.5 , 92.4)	52.7 (48.6 , 56.6)			
2 Non-Hodgkin lymphoma	67,208	67.4 (66.9 , 67.9)	88.1 (86.7 , 89.3)	76.6 (76.0 , 77.2)	58.5 (57.7 , 59.2)			
2(a) Non-Hodgkin lymphoma, B-cell	61,908	67.7 (67.2 , 68.2)	88.5 (87.0 , 89.9)	77.4 (76.7 , 78.0)	59.1 (58.3 , 59.9)			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	3,216	67.2 (65.3 , 69.0)	88.9 (87.2 , 90.4)	35.4 (31.8 , 39.1)	11.5 (7.5 , 16.4)			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	55,792	67.7 (67.2 , 68.3)	85.6 (81.2 , 89.0)	79.0 (78.3 , 79.6)	59.3 (58.5 , 60.1)			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	11,796	78.4 (77.2 , 79.6)	- (- , -)	88.8 (87.4 , 90.1)	73.0 (71.3 , 74.7)			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	10,736	80.7 (79.4 , 81.9)	- (- , -)	91.0 (89.5 , 92.3)	75.4 (73.5 , 77.1)			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	45	28.4 (14.1 , 44.6)	- (- , -)	- (- , -)	15.6 (3.8 , 34.8)			
2(a) 2.1.3. Mantle-cell lymphoma	1,015	57.0 (52.6 , 61.1)	- (- , -)	69.5 (63.3 , 74.8)	49.4 (43.5 , 54.9)			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	1,152	76.6 (72.4 , 80.2)	- (- , -)	85.8 (80.3 , 89.9)	71.4 (65.5 , 76.5)			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	547	72.0 (65.4 , 77.5)	- (- , -)	81.5 (71.7 , 88.1)	66.9 (58.1 , 74.3)			
2(a) 2.2.2. Waldenstrom macroglobulinemia	605	80.5 (74.8 , 85.0)	- (- , -)	89.1 (82.1 , 93.5)	75.5 (67.2 , 82.0)			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	15,035	60.6 (59.6 , 61.6)	83.0 (76.8 , 87.7)	73.8 (72.5 , 75.1)	50.5 (49.1 , 52.0)			
2(a) 2.3.1. DLBCL, NOS ^c	14,846	60.3 (59.3 , 61.3)	84.6 (78.4 , 89.2)	73.6 (72.2 , 74.8)	50.5 (49.0 , 52.0)			
2(a) 2.3.2. Intravascular large B-cell lymphoma	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(a) 2.3.3. Primary effusion lymphoma	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	166	84.1 (76.9 , 89.2)	- (- , -)	86.4 (78.9 , 91.3)	- (- , -)			
2(a) 2.4. Burkitt lymphoma/leukemia	589	56.8 (52.2 , 61.2)	87.9 (79.2 , 93.2)	58.7 (52.3 , 64.5)	36.3 (28.0 , 44.6)			
2(a) 2.5. Marginal-zone lymphoma (MZL)	4,788	90.6 (88.9 , 92.0)	- (- , -)	94.5 (92.8 , 95.8)	87.3 (84.4 , 89.7)			
2(a) 2.5.1. Splenic MZL	403	82.5 (76.1 , 87.4)	- (- , -)	90.4 (83.1 , 94.6)	76.3 (65.2 , 84.3)			
2(a) 2.5.2. Extranodal MZL, MALT ^c type	2,937	94.8 (92.6 , 96.4)	- (- , -)	96.9 (94.9 , 98.1)	92.8 (88.6 , 95.5)			
2(a) 2.5.3. Nodal MZL	1,448	84.1 (80.7 , 86.9)	- (- , -)	89.6 (85.5 , 92.5)	80.4 (75.3 , 84.6)			
2(a) 2.6. Follicular lymphoma	9,089	86.7 (85.6 , 87.8)	- (- , -)	92.2 (91.1 , 93.2)	80.3 (78.2 , 82.3)			
2(a) 2.7. Hairy-cell leukemia	294	91.0 (83.6 , 95.2)	- (- , -)	96.6 (92.1 , 98.5)	79.0 (61.3 , 89.3)			
2(a) 2.8. Plasma cell neoplasms	13,043	43.3 (42.1 , 44.4)	- (- , -)	57.9 (56.1 , 59.6)	33.6 (32.1 , 35.1)			
2(a) 2.8.1. Plasmacytoma	686	59.0 (53.6 , 63.9)	- (- , -)	75.0 (68.3 , 80.5)	42.7 (35.0 , 50.2)			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	12,357	42.4 (41.2 , 43.6)	- (- , -)	56.7 (54.8 , 58.5)	33.2 (31.7 , 34.7)			
2(a) 2.9. Heavy chain disease	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	2,900	68.3 (65.7 , 70.7)	- (- , -)	78.6 (75.3 , 81.5)	62.6 (59.0 , 66.0)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.31 - continued
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2004-2010

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)		
2(b) Non-Hodgkin lymphoma, T-cell	4,161	64.5 (62.7 , 66.3)	84.9 (80.3 , 88.5)	70.5 (68.3 , 72.6)	50.5 (46.9 , 53.9)			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	269	61.8 (55.1 , 67.8)	88.9 (81.0 , 93.7)	47.8 (37.9 , 57.1)	14.3 (3.7 , 31.6)			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	3,851	65.2 (63.2 , 67.0)	83.3 (77.2 , 87.8)	72.2 (69.9 , 74.3)	51.7 (48.1 , 55.2)			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	1,017	90.6 (87.2 , 93.1)	91.4 (66.2 , 98.1)	93.4 (90.1 , 95.7)	83.8 (75.1 , 89.7)			
2(b) 2.1.1. Mycosis fungoides	991	91.9 (88.6 , 94.3)	91.4 (66.2 , 98.1)	93.8 (90.5 , 96.0)	86.2 (79.2 , 90.9)			
2(b) 2.1.2. Sezary syndrome	26	33.9 (10.2 , 59.9)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2. Peripheral T-cell lymphoma	2,272	58.3 (55.8 , 60.8)	86.7 (78.0 , 92.1)	67.5 (64.4 , 70.4)	43.6 (39.4 , 47.7)			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	743	38.0 (33.9 , 42.1)	- (- , -)	47.6 (41.7 , 53.4)	27.4 (21.9 , 33.2)			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	339	48.7 (42.2 , 55.0)	- (- , -)	56.6 (47.4 , 64.9)	42.5 (33.3 , 51.3)			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	48	61.1 (41.2 , 76.1)	- (- , -)	59.2 (32.2 , 78.5)	- (- , -)			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	441	61.2 (55.7 , 66.2)	86.6 (74.8 , 93.1)	70.5 (63.9 , 76.1)	31.4 (21.9 , 41.4)			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	28	26.2 (11.0 , 44.3)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	437	81.8 (75.6 , 86.6)	- (- , -)	87.6 (81.3 , 91.9)	72.9 (60.3 , 82.0)			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	222	92.2 (84.0 , 96.3)	- (- , -)	94.6 (85.7 , 98.0)	81.8 (60.4 , 92.3)			
2(b) 2.3. Adult T-cell leukemia/lymphoma	269	47.2 (40.3 , 53.9)	78.6 (67.6 , 86.3)	32.8 (23.1 , 42.8)	25.8 (14.5 , 38.5)			
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	143	41.6 (31.6 , 51.3)	- (- , -)	41.2 (29.8 , 52.3)	45.3 (25.3 , 63.3)			
2(b) 2.5. T-cell large granular lymphocytic leukemia	75	74.9 (57.1 , 86.1)	- (- , -)	77.3 (52.5 , 90.2)	69.5 (42.9 , 85.5)			
2(b) 2.6. Prolymphocytic leukemia, T-cell	75	22.5 (11.1 , 36.4)	- (- , -)	28.4 (13.4 , 45.4)	19.5 (6.2 , 38.3)			
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	41	27.3 (13.4 , 43.2)	- (- , -)	40.2 (21.1 , 58.6)	- (- , -)			
2(c) Non-Hodgkin lymphoma, unknown lineage	1,139	59.8 (56.2 , 63.1)	88.2 (83.7 , 91.6)	61.1 (54.6 , 66.9)	42.8 (37.1 , 48.4)			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	479	65.9 (61.2 , 70.2)	88.4 (83.8 , 91.7)	43.6 (33.1 , 53.6)	15.1 (7.2 , 25.8)			
2(c) 2. Prolymphocytic leukemia, unknown lineage	25	60.6 (36.4 , 78.0)	- (- , -)	- (- , -)	- (- , -)			
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	635	54.4 (49.2 , 59.4)	- (- , -)	69.0 (60.8 , 75.9)	47.8 (41.2 , 54.1)			
2(*) 1. Total precursor lymphoma/leukemia ^d	3,964	66.7 (65.1 , 68.4)	88.9 (87.4 , 90.2)	37.7 (34.5 , 41.0)	12.4 (8.8 , 16.6)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	38	46.4 (25.6 , 64.8)	- (- , -)	- (- , -)	- (- , -)			
4 Lymphoid neoplasm, NOS ^c	2,167	48.3 (45.5 , 51.0)	86.8 (64.3 , 95.6)	65.1 (60.8 , 69.2)	39.7 (36.3 , 43.1)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).


^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.

Figure 19.1

SEER Observed Incidence, SEER Delay Adjusted Incidence and US Death Rates^a Non-Hodgkin Lymphoma, by Race and Sex




^a Source: SEER 9 areas and US Mortality Files (National Center for Health Statistics, CDC). Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103). Regression lines and APCs are calculated using the Joinpoint Regression Program Version 4.1.0, April 2014, National Cancer Institute. The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.
* The APC is significantly different from zero ($p < 0.05$).

Figure 19.2

SEER Incidence and US Death Rates^a Non-Hodgkin Lymphoma, Both Sexes

Joinpoint Analyses for Whites and Blacks from 1975-2011

and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2011



Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey,

^a Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).


Regression lines are calculated using the Joinpoint Regression Program Version 4.1.0, April 2014, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2011 period allow a maximum of 5 joinpoints. Analyses for other ethnic groups during the period 1992-2011 allow a maximum of 3 joinpoints.

^b API = Asian/Pacific Islander.

^c AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties. Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from New Hampshire and Oklahoma.

Figure 19.3


Non-Hodgkin Lymphoma Incidence Rates, 1980 vs 2011 Males by Age at Diagnosis and SEER area



Source: SEER 9 areas. Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103).

Figure 19.4


Non-Hodgkin Lymphoma SEER Incidence by Age 1975-1977 vs 2009-2011 All Races, Males



Source: SEER 9 areas. Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103).

Figure 19.5

SEER Observed Incidence and SEER Delay Adjusted Incidence Rates^a SEER 9 Areas Compared to SEER 13 Areas Non-Hodgkin Lymphoma, Male, by Race




● SEER 9 Delay-Adj. Incidence
 ○ SEER 9 Observed Incidence
 ■ SEER 13 Delay-Adj. Incidence
 □ SEER 13 Observed Incidence

^a Source: SEER 9 areas and SEER 13 areas. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103). Regression lines and APCs are calculated using the Joinpoint Regression Program Version 4.1.0, April 2014, National Cancer Institute. The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.
* The APC is significantly different from zero (p < 0.05).

Figure 19.6

SEER Observed Incidence and SEER Delay Adjusted Incidence Rates^a SEER 9 Areas Compared to SEER 13 Areas Non-Hodgkin Lymphoma, Female, by Race




● SEER 9 Delay-Adj. Incidence
 ○ SEER 9 Observed Incidence
 ■ SEER 13 Delay-Adj. Incidence
 □ SEER 13 Observed Incidence

^a Source: SEER 9 areas and SEER 13 areas. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103). Regression lines and APCs are calculated using the Joinpoint Regression Program Version 4.1.0, April 2014, National Cancer Institute. The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.
 * The APC is significantly different from zero (p < 0.05).

Figure 19.7

Non-Hodgkin Lymphoma 5-Year SEER Conditional Relative Survival and 95% Confidence Intervals

Probability of surviving the next 5 years given the cohort
has already survived 0, 1, or 3 years
1998-2010 by stage at diagnosis



Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG contribute cases for diagnosis years 2000-2009. The remaining 13 SEER Areas contribute cases for the entire period 1998-2010. Percent surviving is not shown if based on less than 25 cases. Confidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error.